OPULENT PHARMA specialize in key areas like Organic Custom Synthesis & Chemical Development, and can offer chemical synthesis services of desired compounds from milligram to kg level. We are strong and currently focused in Pharmaceutical Impurity Synthesis but we also provide synthesis support for API, Pharmaceutical Intermediates, Specialty & Research Chemicals, Building Blocks & Library Synthesis, Custom Synthesis. We can offer more than 4000 Impurities (LIST ENCLOSED) from STOCK at an very competitive price, also feel free to share other requirements as the products we can offer are not limited to the list.
Established in the year 2005, we, “Anant Pharmaceuticals Pvt. Ltd.”, are a coveted manufacturer and supplier of high quality Pharmaceutical Reference Material. Our range of products encompasses impurities and degradation products as per the leading pharmacopeial bodies. We supply impurity samples as per IP / BP / EP / USP etc. With a mission of timely delivery with consistent product quality our vision is to become a partner of choice to our clients by service excellence. All the impurity standards are tested using the methods reported in the current pharmacopeia monograph whenever available or with the method compatible with customer’s specific analytical procedures. Products are characterized by sophisticated analytical methods like LCMS & NMR. The characterization data is supplied with the sample along with the standard COA. Our laboratories are equipped with modern equipments and are designed for maximum efficiency.
Veeprho Laboratories Pvt Ltd is an emerging pharmaceutical company that specializes in isolating and purifying impurities using preparative HPLC and custom synthesis of complex molecules. They offer capabilities for providing impurity standards, synthesis of impurities/metabolites/intermediates to support the pharmaceutical industry. The document lists over 100 rare impurity products with their catalogue numbers and corresponding parent drugs.
VEEPRHO LABORATORIES PVT LTD a company with a focus on
1. Impurity isolation from API or drug products by Preprative HPLC.
2. Synthesis of Impurities/Metabolite.
3. Intermediates and APIs, development and manufacturing a Compliance Analytical Lab.
The document lists various impurity standards for pharmaceutical drugs. It provides the catalogue number, parent drug name, and specific impurity name for each standard. There are over 160 entries listing impurities for drugs like acetazolamide, acrivastine, aripiprazole, atorvastatin, azithromycin, carvedilol, cetirizine and many others.
OPULENT PHARMA specialize in key areas like Organic Custom Synthesis & Chemical Development, and can offer chemical synthesis services of desired compounds from milligram to kg level. We are strong and currently focused in Pharmaceutical Impurity Synthesis but we also provide synthesis support for API, Pharmaceutical Intermediates, Specialty & Research Chemicals, Building Blocks & Library Synthesis, Custom Synthesis. We can offer more than 4000 Impurities (LIST ENCLOSED) from STOCK at an very competitive price, also feel free to share other requirements as the products we can offer are not limited to the list.
Alpha Chemika is an ISO 9001:2000 certified company located in the UK that manufactures a wide range of over 7,000 laboratory chemicals. It has been in business for over 32 years and is one of the top 5 chemical companies in India. The company aims to provide its customers with the highest quality chemicals and materials at the lowest possible cost.
Established in the year 2005, we, “Anant Pharmaceuticals Pvt. Ltd.”, are a coveted manufacturer and supplier of high quality Pharmaceutical Reference Material. Our range of products encompasses impurities and degradation products as per the leading pharmacopeial bodies. We supply impurity samples as per IP / BP / EP / USP etc. With a mission of timely delivery with consistent product quality our vision is to become a partner of choice to our clients by service excellence. All the impurity standards are tested using the methods reported in the current pharmacopeia monograph whenever available or with the method compatible with customer’s specific analytical procedures. Products are characterized by sophisticated analytical methods like LCMS & NMR. The characterization data is supplied with the sample along with the standard COA. Our laboratories are equipped with modern equipments and are designed for maximum efficiency.
Veeprho Laboratories Pvt Ltd is an emerging pharmaceutical company that specializes in isolating and purifying impurities using preparative HPLC and custom synthesis of complex molecules. They offer capabilities for providing impurity standards, synthesis of impurities/metabolites/intermediates to support the pharmaceutical industry. The document lists over 100 rare impurity products with their catalogue numbers and corresponding parent drugs.
VEEPRHO LABORATORIES PVT LTD a company with a focus on
1. Impurity isolation from API or drug products by Preprative HPLC.
2. Synthesis of Impurities/Metabolite.
3. Intermediates and APIs, development and manufacturing a Compliance Analytical Lab.
The document lists various impurity standards for pharmaceutical drugs. It provides the catalogue number, parent drug name, and specific impurity name for each standard. There are over 160 entries listing impurities for drugs like acetazolamide, acrivastine, aripiprazole, atorvastatin, azithromycin, carvedilol, cetirizine and many others.
OPULENT PHARMA specialize in key areas like Organic Custom Synthesis & Chemical Development, and can offer chemical synthesis services of desired compounds from milligram to kg level. We are strong and currently focused in Pharmaceutical Impurity Synthesis but we also provide synthesis support for API, Pharmaceutical Intermediates, Specialty & Research Chemicals, Building Blocks & Library Synthesis, Custom Synthesis. We can offer more than 4000 Impurities (LIST ENCLOSED) from STOCK at an very competitive price, also feel free to share other requirements as the products we can offer are not limited to the list.
Alpha Chemika is an ISO 9001:2000 certified company located in the UK that manufactures a wide range of over 7,000 laboratory chemicals. It has been in business for over 32 years and is one of the top 5 chemical companies in India. The company aims to provide its customers with the highest quality chemicals and materials at the lowest possible cost.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Hiranandani Hospital in Powai, Mumbai, is a premier healthcare institution that has been serving the community with exceptional medical care since its establishment. As a part of the renowned Hiranandani Group, the hospital is committed to delivering world-class healthcare services across a wide range of specialties, including kidney transplantation. With its state-of-the-art facilities, advanced medical technology, and a team of highly skilled healthcare professionals, Hiranandani Hospital has earned a reputation as a trusted name in the healthcare industry. The hospital's patient-centric approach, coupled with its focus on innovation and excellence, ensures that patients receive the highest standard of care in a compassionate and supportive environment.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
2024 State of Marketing Report – by HubspotMarius Sescu
https://www.hubspot.com/state-of-marketing
· Scaling relationships and proving ROI
· Social media is the place for search, sales, and service
· Authentic influencer partnerships fuel brand growth
· The strongest connections happen via call, click, chat, and camera.
· Time saved with AI leads to more creative work
· Seeking: A single source of truth
· TLDR; Get on social, try AI, and align your systems.
· More human marketing, powered by robots
ChatGPT is a revolutionary addition to the world since its introduction in 2022. A big shift in the sector of information gathering and processing happened because of this chatbot. What is the story of ChatGPT? How is the bot responding to prompts and generating contents? Swipe through these slides prepared by Expeed Software, a web development company regarding the development and technical intricacies of ChatGPT!
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Hiranandani Hospital in Powai, Mumbai, is a premier healthcare institution that has been serving the community with exceptional medical care since its establishment. As a part of the renowned Hiranandani Group, the hospital is committed to delivering world-class healthcare services across a wide range of specialties, including kidney transplantation. With its state-of-the-art facilities, advanced medical technology, and a team of highly skilled healthcare professionals, Hiranandani Hospital has earned a reputation as a trusted name in the healthcare industry. The hospital's patient-centric approach, coupled with its focus on innovation and excellence, ensures that patients receive the highest standard of care in a compassionate and supportive environment.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
2024 State of Marketing Report – by HubspotMarius Sescu
https://www.hubspot.com/state-of-marketing
· Scaling relationships and proving ROI
· Social media is the place for search, sales, and service
· Authentic influencer partnerships fuel brand growth
· The strongest connections happen via call, click, chat, and camera.
· Time saved with AI leads to more creative work
· Seeking: A single source of truth
· TLDR; Get on social, try AI, and align your systems.
· More human marketing, powered by robots
ChatGPT is a revolutionary addition to the world since its introduction in 2022. A big shift in the sector of information gathering and processing happened because of this chatbot. What is the story of ChatGPT? How is the bot responding to prompts and generating contents? Swipe through these slides prepared by Expeed Software, a web development company regarding the development and technical intricacies of ChatGPT!
Product Design Trends in 2024 | Teenage EngineeringsPixeldarts
The realm of product design is a constantly changing environment where technology and style intersect. Every year introduces fresh challenges and exciting trends that mold the future of this captivating art form. In this piece, we delve into the significant trends set to influence the look and functionality of product design in the year 2024.
How Race, Age and Gender Shape Attitudes Towards Mental HealthThinkNow
Mental health has been in the news quite a bit lately. Dozens of U.S. states are currently suing Meta for contributing to the youth mental health crisis by inserting addictive features into their products, while the U.S. Surgeon General is touring the nation to bring awareness to the growing epidemic of loneliness and isolation. The country has endured periods of low national morale, such as in the 1970s when high inflation and the energy crisis worsened public sentiment following the Vietnam War. The current mood, however, feels different. Gallup recently reported that national mental health is at an all-time low, with few bright spots to lift spirits.
To better understand how Americans are feeling and their attitudes towards mental health in general, ThinkNow conducted a nationally representative quantitative survey of 1,500 respondents and found some interesting differences among ethnic, age and gender groups.
Technology
For example, 52% agree that technology and social media have a negative impact on mental health, but when broken out by race, 61% of Whites felt technology had a negative effect, and only 48% of Hispanics thought it did.
While technology has helped us keep in touch with friends and family in faraway places, it appears to have degraded our ability to connect in person. Staying connected online is a double-edged sword since the same news feed that brings us pictures of the grandkids and fluffy kittens also feeds us news about the wars in Israel and Ukraine, the dysfunction in Washington, the latest mass shooting and the climate crisis.
Hispanics may have a built-in defense against the isolation technology breeds, owing to their large, multigenerational households, strong social support systems, and tendency to use social media to stay connected with relatives abroad.
Age and Gender
When asked how individuals rate their mental health, men rate it higher than women by 11 percentage points, and Baby Boomers rank it highest at 83%, saying it’s good or excellent vs. 57% of Gen Z saying the same.
Gen Z spends the most amount of time on social media, so the notion that social media negatively affects mental health appears to be correlated. Unfortunately, Gen Z is also the generation that’s least comfortable discussing mental health concerns with healthcare professionals. Only 40% of them state they’re comfortable discussing their issues with a professional compared to 60% of Millennials and 65% of Boomers.
Race Affects Attitudes
As seen in previous research conducted by ThinkNow, Asian Americans lag other groups when it comes to awareness of mental health issues. Twenty-four percent of Asian Americans believe that having a mental health issue is a sign of weakness compared to the 16% average for all groups. Asians are also considerably less likely to be aware of mental health services in their communities (42% vs. 55%) and most likely to seek out information on social media (51% vs. 35%).
AI Trends in Creative Operations 2024 by Artwork Flow.pdfmarketingartwork
Creative operations teams expect increased AI use in 2024. Currently, over half of tasks are not AI-enabled, but this is expected to decrease in the coming year. ChatGPT is the most popular AI tool currently. Business leaders are more actively exploring AI benefits than individual contributors. Most respondents do not believe AI will impact workforce size in 2024. However, some inhibitions still exist around AI accuracy and lack of understanding. Creatives primarily want to use AI to save time on mundane tasks and boost productivity.
Organizational culture includes values, norms, systems, symbols, language, assumptions, beliefs, and habits that influence employee behaviors and how people interpret those behaviors. It is important because culture can help or hinder a company's success. Some key aspects of Netflix's culture that help it achieve results include hiring smartly so every position has stars, focusing on attitude over just aptitude, and having a strict policy against peacocks, whiners, and jerks.
PEPSICO Presentation to CAGNY Conference Feb 2024Neil Kimberley
PepsiCo provided a safe harbor statement noting that any forward-looking statements are based on currently available information and are subject to risks and uncertainties. It also provided information on non-GAAP measures and directing readers to its website for disclosure and reconciliation. The document then discussed PepsiCo's business overview, including that it is a global beverage and convenient food company with iconic brands, $91 billion in net revenue in 2023, and nearly $14 billion in core operating profit. It operates through a divisional structure with a focus on local consumers.
Content Methodology: A Best Practices Report (Webinar)contently
This document provides an overview of content methodology best practices. It defines content methodology as establishing objectives, KPIs, and a culture of continuous learning and iteration. An effective methodology focuses on connecting with audiences, creating optimal content, and optimizing processes. It also discusses why a methodology is needed due to the competitive landscape, proliferation of channels, and opportunities for improvement. Components of an effective methodology include defining objectives and KPIs, audience analysis, identifying opportunities, and evaluating resources. The document concludes with recommendations around creating a content plan, testing and optimizing content over 90 days.
How to Prepare For a Successful Job Search for 2024Albert Qian
The document provides guidance on preparing a job search for 2024. It discusses the state of the job market, focusing on growth in AI and healthcare but also continued layoffs. It recommends figuring out what you want to do by researching interests and skills, then conducting informational interviews. The job search should involve building a personal brand on LinkedIn, actively applying to jobs, tailoring resumes and interviews, maintaining job hunting as a habit, and continuing self-improvement. Once hired, the document advises setting new goals and keeping skills and networking active in case of future opportunities.
A report by thenetworkone and Kurio.
The contributing experts and agencies are (in an alphabetical order): Sylwia Rytel, Social Media Supervisor, 180heartbeats + JUNG v MATT (PL), Sharlene Jenner, Vice President - Director of Engagement Strategy, Abelson Taylor (USA), Alex Casanovas, Digital Director, Atrevia (ES), Dora Beilin, Senior Social Strategist, Barrett Hoffher (USA), Min Seo, Campaign Director, Brand New Agency (KR), Deshé M. Gully, Associate Strategist, Day One Agency (USA), Francesca Trevisan, Strategist, Different (IT), Trevor Crossman, CX and Digital Transformation Director; Olivia Hussey, Strategic Planner; Simi Srinarula, Social Media Manager, The Hallway (AUS), James Hebbert, Managing Director, Hylink (CN / UK), Mundy Álvarez, Planning Director; Pedro Rojas, Social Media Manager; Pancho González, CCO, Inbrax (CH), Oana Oprea, Head of Digital Planning, Jam Session Agency (RO), Amy Bottrill, Social Account Director, Launch (UK), Gaby Arriaga, Founder, Leonardo1452 (MX), Shantesh S Row, Creative Director, Liwa (UAE), Rajesh Mehta, Chief Strategy Officer; Dhruv Gaur, Digital Planning Lead; Leonie Mergulhao, Account Supervisor - Social Media & PR, Medulla (IN), Aurelija Plioplytė, Head of Digital & Social, Not Perfect (LI), Daiana Khaidargaliyeva, Account Manager, Osaka Labs (UK / USA), Stefanie Söhnchen, Vice President Digital, PIABO Communications (DE), Elisabeth Winiartati, Managing Consultant, Head of Global Integrated Communications; Lydia Aprina, Account Manager, Integrated Marketing and Communications; Nita Prabowo, Account Manager, Integrated Marketing and Communications; Okhi, Web Developer, PNTR Group (ID), Kei Obusan, Insights Director; Daffi Ranandi, Insights Manager, Radarr (SG), Gautam Reghunath, Co-founder & CEO, Talented (IN), Donagh Humphreys, Head of Social and Digital Innovation, THINKHOUSE (IRE), Sarah Yim, Strategy Director, Zulu Alpha Kilo (CA).
Trends In Paid Search: Navigating The Digital Landscape In 2024Search Engine Journal
The search marketing landscape is evolving rapidly with new technologies, and professionals, like you, rely on innovative paid search strategies to meet changing demands.
It’s important that you’re ready to implement new strategies in 2024.
Check this out and learn the top trends in paid search advertising that are expected to gain traction, so you can drive higher ROI more efficiently in 2024.
You’ll learn:
- The latest trends in AI and automation, and what this means for an evolving paid search ecosystem.
- New developments in privacy and data regulation.
- Emerging ad formats that are expected to make an impact next year.
Watch Sreekant Lanka from iQuanti and Irina Klein from OneMain Financial as they dive into the future of paid search and explore the trends, strategies, and technologies that will shape the search marketing landscape.
If you’re looking to assess your paid search strategy and design an industry-aligned plan for 2024, then this webinar is for you.
5 Public speaking tips from TED - Visualized summarySpeakerHub
From their humble beginnings in 1984, TED has grown into the world’s most powerful amplifier for speakers and thought-leaders to share their ideas. They have over 2,400 filmed talks (not including the 30,000+ TEDx videos) freely available online, and have hosted over 17,500 events around the world.
With over one billion views in a year, it’s no wonder that so many speakers are looking to TED for ideas on how to share their message more effectively.
The article “5 Public-Speaking Tips TED Gives Its Speakers”, by Carmine Gallo for Forbes, gives speakers five practical ways to connect with their audience, and effectively share their ideas on stage.
Whether you are gearing up to get on a TED stage yourself, or just want to master the skills that so many of their speakers possess, these tips and quotes from Chris Anderson, the TED Talks Curator, will encourage you to make the most impactful impression on your audience.
See the full article and more summaries like this on SpeakerHub here: https://speakerhub.com/blog/5-presentation-tips-ted-gives-its-speakers
See the original article on Forbes here:
http://www.forbes.com/forbes/welcome/?toURL=http://www.forbes.com/sites/carminegallo/2016/05/06/5-public-speaking-tips-ted-gives-its-speakers/&refURL=&referrer=#5c07a8221d9b
ChatGPT and the Future of Work - Clark Boyd Clark Boyd
Everyone is in agreement that ChatGPT (and other generative AI tools) will shape the future of work. Yet there is little consensus on exactly how, when, and to what extent this technology will change our world.
Businesses that extract maximum value from ChatGPT will use it as a collaborative tool for everything from brainstorming to technical maintenance.
For individuals, now is the time to pinpoint the skills the future professional will need to thrive in the AI age.
Check out this presentation to understand what ChatGPT is, how it will shape the future of work, and how you can prepare to take advantage.
The document provides career advice for getting into the tech field, including:
- Doing projects and internships in college to build a portfolio.
- Learning about different roles and technologies through industry research.
- Contributing to open source projects to build experience and network.
- Developing a personal brand through a website and social media presence.
- Networking through events, communities, and finding a mentor.
- Practicing interviews through mock interviews and whiteboarding coding questions.
Google's Just Not That Into You: Understanding Core Updates & Search IntentLily Ray
1. Core updates from Google periodically change how its algorithms assess and rank websites and pages. This can impact rankings through shifts in user intent, site quality issues being caught up to, world events influencing queries, and overhauls to search like the E-A-T framework.
2. There are many possible user intents beyond just transactional, navigational and informational. Identifying intent shifts is important during core updates. Sites may need to optimize for new intents through different content types and sections.
3. Responding effectively to core updates requires analyzing "before and after" data to understand changes, identifying new intents or page types, and ensuring content matches appropriate intents across video, images, knowledge graphs and more.
A brief introduction to DataScience with explaining of the concepts, algorithms, machine learning, supervised and unsupervised learning, clustering, statistics, data preprocessing, real-world applications etc.
It's part of a Data Science Corner Campaign where I will be discussing the fundamentals of DataScience, AIML, Statistics etc.
Time Management & Productivity - Best PracticesVit Horky
Here's my presentation on by proven best practices how to manage your work time effectively and how to improve your productivity. It includes practical tips and how to use tools such as Slack, Google Apps, Hubspot, Google Calendar, Gmail and others.
The six step guide to practical project managementMindGenius
The six step guide to practical project management
If you think managing projects is too difficult, think again.
We’ve stripped back project management processes to the
basics – to make it quicker and easier, without sacrificing
the vital ingredients for success.
“If you’re looking for some real-world guidance, then The Six Step Guide to Practical Project Management will help.”
Dr Andrew Makar, Tactical Project Management
2.
A Beta‐Epoxyabiraterone Acetate
A 7‐Ketoabiraterone Acetate
A Abiraterone Methyl Ether 1470276‐23‐3
A Abiraterone Acetate N‐Oxide
A Abiraterone Acetate‐5,6‐Epoxide
A Product: ACARBOSE IMPURITIES
A Acarbose EP Impurity A 1013621‐79‐8
A Acarbose EP Impurity C 610271‐07‐3
A Acarbose EP Impurity E 1220983‐28‐7
A Acarbose EP Impurity F 83116‐09‐0
A Acarbose EP Impurity G 1013621‐73‐2
A Product: ACEBUTOL IMPURITIES
A Acebutolol EP Impurity A (Acebutolol Epoxypropoxy Impurity) 28197‐66‐2
A Acebutolol EP Impurity B/ Acebutolol Related Compound B (Diacetolol)
22568‐64‐5
73899‐76‐0
A Acebutolol EP Impurity C 40188‐45‐2
A Acebutolol EP Impurity D 57898‐80‐3
A Acebutolol EP Impurity E (Acebutolol Desacetyl Impurity) 1432053‐72‐9
A Acebutolol EP Impurity J 57898‐79‐0
A Product: ACECLOFENAC IMPURITIES
A Aceclofenac EP Impurity A (Diclofenac)
15307‐86‐5
15307‐79‐6
A Aceclofenac EP Impurity B (Diclofenac Methyl Ester) 15307‐78‐5
A Aceclofenac EP Impurity C (Diclofenac Ethyl Ester) 15307‐77‐4
A Aceclofenac EP Impurity D (Aceclofenac Methyl Ester) 139272‐66‐5
A Aceclofenac EP Impurity E (Aceclofenac Ethyl Ester) 139272‐67‐6
A Aceclofenac EP Impurity F (Aceclofenac Benzyl Ester) 100499‐89‐6
A Aceclofenac EP Impurity G (Acetic Aceclofenac) 1215709‐75‐3
A Aceclofenac Impurity EP H (Diacetic Aceclofenac) 1216495‐92‐9
A Aceclofenac EP Impurity I (Diclofenac EP Impurity A/ Diclofenac USP Related Compound A/ Diclofenac Amide) 15362‐40‐0
3.
A Product: ACEMETACIN IMPURITIES
A Acemetacin EP Impurity A (Indomethacin EP Impurity A/ Indomethacin Related Compound B/ Bezafibrate EP Impurity B) 74‐11‐3
A Acemetacin EP Impurity B (Indomethacin) 53‐86‐1
A Product: ACESULFAME POTTASIUM IMPURITIES
A Acesulfame Potassium Impurity A/ Acetoacetamide 5977‐14‐0
A Product: ACETAZOLAMIDE IMPURITIES
A Acetazolamide EP Impurity A 60320‐32‐3
A Acetazolamide EP Impurity B 5393‐55‐5
A Acetazolamide EP Impurity C 32873‐56‐6
A Acetazolamide EP Impurity D 14949‐00‐9
A Acetazolamide EP Impurity E 827026‐60‐8
A Acetazolamide EP Impurity G 2349‐67‐9
A Product: ACETYLSALICYLIC ACID IMPURITIES/ ASPIRIN IMPURITIES
A Acetylsalicylic Acid EP Impurity A (Butyl Parahydroxybenzoate EP Impurity A/ p‐Salicylic Acid/ 4‐Hydroxybenzoic acid) 99‐96‐7
A Acetylsalicylic Acid EP Impurity B (4‐Hydroxyisophthalic Acid) 636‐46‐4
A
Acetylsalicylic Acid EP Impurity C (Salicylic Acid/ Lamivudine EP Impurity C/ Mesalazine EP Impurity H/ Sulfasalazine EP
Impurity H) 69‐72‐7
A Acetylsalicylic Acid EP Impurity D (Acetylsalicylsalicylic acid) 530‐75‐6
A Acetylsalicylic Acid EP Impurity E (Salsalate/ Salicylsalicylic acid) 552‐94‐3
A Acetylsalicylic Acid EP Impurity F (Acetylsalicylic Anhydride) 1466‐82‐6
A Salicylaldehyde Azine 959‐36‐4
A Product: ACYCLOVIR IMPURITIES
A Acyclovir EP Impurity A (O‐Acetyl Aciclovir/ Valaciclovir EP Impurity I/ Valaciclovir Related Compund I) 102728‐64‐3
A Acyclovir EP Impurity B (Guanine/ Valaciclovir EP Impurity A/ Valaciclovir Related Compound A) 73‐40‐5
A Acyclovir EP Impurity C (Aciclovir N7‐Isomer) 91702‐61‐3
A Acyclovir Impurity D 59277‐91‐7
A Acyclovir EP Impurity F (N2‐Acetyl Aciclovir) 110104‐37‐5
A Acyclovir EP Impurity G (Aciclovir N,O‐Diacetate) 75128‐73‐3
4.
A Acyclovir Impurity H 133186‐23‐9
A Acyclovir EP Impurity J 166762‐90‐9
A Acyclovir EP Impurity L 3056‐33‐5
A Acyclovir EP Impurity M (N,O‐Diacetate Isoacyclovir) 91702‐60‐2
A Acyclovir Impurity N
A Acyclovir EP Impurity P 23169‐33‐7
A Acyclovir L‐Alaninate (Valaciclovir EP Impurity H/ Valaciclovir Related Compund H/ Didesmethyl Valacyclovir)
84499‐64‐9
84499‐63‐8
A Acyclovir L‐Isoleucinate (Valaciclovir EP Impurity J) 142963‐63‐1
A Acyclovir N‐Methylene Dimer (Valaciclovir EP Impurity L) 1797131‐64‐6
A Acyclovir D‐Valinate (Valaciclovir EP Impurity R/ D‐Valacyclovir)
142963‐60‐8
124832‐28‐6
A 2‐amino‐8‐hydroxy‐9‐((2‐hydroxyethoxy)methyl)‐1,9‐dihydro‐6H‐purin‐6‐one 80685‐23‐0
A Product: ADAPALENE IMPURITIES
A Adapalene EP Impurity B (Adapalene 3‐Hydroxy Impurity) 1346599‐76‐5
A Adapalene EP Impurity C/ Adapalene Related Compound C (o‐Adamantylanisole) 43109‐77‐9
A Product: ADRENALINE IMPURITIES/ EPINEPHRINE IMPURITIES
A Adrenaline EP Impurity B 51‐41‐2
A Adrenaline Impurity C/ Epinephrine Impurity C (Adrenalone)
99‐45‐6
62‐13‐5
A Adrenaline EP Impurity D 1095714‐91‐2
A Adrenaline Impurity E/ Epinephrine Impurity E 36467‐25‐1
A Adrenaline EP Impurity F 78995‐75‐2
A Epinephrine Sulfonic Acid 26405‐77‐6
A Product: AGOMELATINE IMPURITIES
A Agomelatine Dimer Acetamide 1385018‐58‐5
A Agomelatine Desmethyl Impurity 152302‐45‐9
A 7‐Methoxy‐1‐naphthaleneacetonitrile 138113‐08‐3
A Product: ALBENDAZOLE IMPURITIES
A Albendazole EP Impurity A (Albendazole Amine/ Desmethoxycarbonyl Albendazole) 80983‐36‐4
5.
A Albendazole EP Impurity B (Albendazole Sulfoxide/ Ricobendazole) 54029‐12‐8
A Albendazole EP Impurity C (Albendazole Sulfone) 75184‐71‐3
A Albendazole EP Impurity D (Desmethoxycarbonyl Albendazole Sulfone) 80983‐34‐2
A Albendazole EP Impurity E (Carbendazim) 10605‐21‐7
A Albendazole EP Impurity F 80983‐45‐5
A Albendazole EP Impurity G (Ethyl Albendazole)
A Albendazole EP Impurity H
A Albendazole EP Impurity I (Oxibendazole) 20559‐55‐1
A Albendazole EP Impurity J 946498‐41‐5
A Albendazole EP Impurity K 70484‐51‐4
A Albendazole EP Impurity L 108579‐67‐5
A O‐Desmethyl‐O‐ethyl Albendazole 139751‐05‐6
A Product: ALFUZOSIN IMPURITIES
A Alfuzosin EP Impurity A/ Alfuzosin Related Compund A (Alfuzosin Tetradehydro Impurity)
98902‐36‐4
98902‐29‐5
A
Alfuzosin EP Impurity B (Prazosin EP Impurity A/ Terazosin EP Impurity A/ Doxazosin EP Impurity F/ Doxazosin Related
Compund C) 23680‐84‐4
A Alfuzosin EP Impurity C
98902‐34‐2
72104‐34‐8
A Alfuzosin EP Impurity D / Alfuzosin Related Compound D (Alfuzosin Aminopropyl Impurity)
76362‐29‐3
81403‐69‐2
A Alfuzosin EP Impurity E
1796934‐51‐4
1026411‐59‐5
A Alfuzosin EP Impurity F 19216‐53‐6
A Alfuzosin EP Impurity G (Dimer) 928780‐95‐4
A (2‐Chloro‐6,7‐dimethoxyquinazoline‐4‐yl)‐(3,4‐dimethoxyphenyl)‐amine 144511‐78‐4
A Product: ALIMEMAZINE IMPURITIES
A Alimemazine EP Impurity C (Promethazine EP Impurity A/ Phenothiazine) 92‐84‐2
A Product: ALLOPURINOL IMPURITIES
6.
A Allopurinol EP impurity A/ Allopurinol Related Compound A
5334‐31‐6
27511‐79‐1
A Allopurinol EP impurity B/ Allopurinol Related Compound B 22407‐20‐1
A Allopurinol EP impurity C/ Allopurinol Related Compound C 1346604‐13‐4
A Allopurinol EP impurity D/ Allopurinol Related Compound D 6994‐25‐8
A Allopurinol EP Impurity E/ Allopurinol Related Compound E 31055‐19‐3
A 2‐cyano‐3‐morpholinoacrylamide 25229‐97‐4
A Product: ALMOTRIPTAN IMPURITIES
A Almotriptan Related Compound A (N‐Hydroxymethyl Almotriptan) 1018676‐02‐2
A Almotriptan Related Compound B (Almotriptan Didesmethyl Impurity) 181178‐24‐5
A Almotriptan Related Compound C (N‐Desmethyl Almotriptan) 334981‐12‐3
A Almotriptan Related Compound D (Almotriptan N‐Oxide)
603137‐43‐5
1391054‐49‐1
A Product: ALOGLIPTIN IMPURITIES
A Alogliptin‐1‐oxo‐1‐de(piperidin‐3‐amine) 1246610‐72‐9
A 6‐Chloro‐3‐methyluracil 4318‐56‐3
A Alogliptin 6‐Chloro Impurity 865758‐96‐9
A 2‐Cyanobenzyl bromide 22115‐41‐9
A Alogliptin S‐Isomer
1108732‐05‐3
1638544‐64‐5
A 4,6‐Dichloro‐2‐(methylthio)pyrimidine 6299‐25‐8
A 4,6‐Dichloro‐2‐(methylsulfonyl)pyrimidine 4489‐34‐3
A 6‐Chloro‐2‐(methylthio)pyrimidin‐4‐ol 6632‐63‐9
A Product: ALPRAZOLAM IMPURITIES
A Alprazolam EP Impurity G 448950‐89‐8
A Product: ALTIZIDE IMPURITIES
A
Altizide EP Impurity A (Hydrochlorothiazide EP Impurity B/ Hydrochlorothiazide Related Compound A/ Benzothiadiazine
Related Compound A/ Salamide ) 121‐30‐2
A Product: AMANTADINE IMPURITIES
A Amantadine EP Impurity B (N‐Acetyl Amantadine) 880‐52‐4
7.
A Product: AMBRISENTAN IMPURITIES
A Ambrisentan N‐Oxide
A Ambrisentan Hydroxy Acid Impurity 178306‐52‐0
A Product: AMBROXOL IMPURITIES
A Ambroxol EP Impurity A (Bromhexine EP Impurity A) 50739‐76‐9
A Ambroxol EP Impurity B
18683‐95‐9
15942‐08‐2
A Ambroxol EP Impurity C (Dehydro Ambroxol) 50910‐53‐7
A Ambroxol EP Impurity D (cis‐Ambroxol HCl/ Acebrophylline Impurity D) 107814‐37‐9
A Ambroxol EP Impurity E (Bromhexine EP Impurity B) 50910‐55‐9
A Product: AMFENAC IMPURITIES
A 2‐Amino‐3‐benzoyl‐α‐oxo‐benzeneacetic Acid 126849‐31‐8
A 7‐Benzoylindoline‐2,3‐dione 70803‐94‐0
A Product: AMINOCAPROIC ACID IMPURITIES
A 6‐Aminocaproic Acid Dimer 2014‐58‐6
A Product: AMIODARONE IMPURITIES
A Amiodarone EP Impurity B/ Amiodarone Related Compound B (Desethyl Amiodarone)
83409‐32‐9
96027‐74‐6
A Amiodarone EP Impurity D/ Amiodarone Related Compound D 1951‐26‐4
A Amiodarone EP Impurity E/ Amiodarone Related Compound E 52490‐15‐0
A Amiodarone EP Impurity F/ Amiodarone Related Compound F 147030‐50‐0
A Amiodarone EP Impurity H/ Amiodarone Related Compound H 869‐24‐9
A Amiodarone Methoxy Impurity 83790‐87‐8
A 2‐butyl benzofuran 4265‐27‐4
A Product: AMISULPIRIDE IMPURITIES
A (2S)‐2‐Aminomethyl‐1‐ethylpyrrolidine 22795‐99‐9
A Product: AMITRAZ IMPURITIES
A 2,4‐dimethylaniline 95‐68‐1
A Product: AMITRIPTYLINE IMPURITIES
8.
A
Amitriptyline EP Impurity A/ Amitriptyline Related Compound A (Nortriptyline EP Impurity A/ Cyproheptadine EP
Impurity B/ Dibenzosuberone) 1210‐35‐1
A Amitriptyline EP Impurity B (Cyclobenzaprine) 6202‐23‐9
A Amitriptyline EP Impurity C (Nortriptyline)
72‐69‐5
894‐71‐3
A Amitriptyline EP Impurity D/ Amitriptyline Related Compound B (Nortriptyline EP Impurity D/ Amitriptynol) 1159‐03‐1
A Amitriptyline EP Impurity G (Dibenzosuberol/ Nortriptyline EP Impurity I) 1210‐34‐0
A Amitriptyline N‐Oxide (Nortriptyline EP Impurity J) 4317‐14‐0
A Product: AMLODIPINE IMPURITIES
A Amlodipine Impurity‐A (EP) /Amlodipine Related Compound D (Phthaloyl Amlodipine) 88150‐62‐3
A Amlodipine Impurity‐B (EP) (Methyl amino phthaloyl Amlodipinee) 721958‐72‐1
A Amlodipine EP Impurity C (Bis(aminoethoxy) Amlodipine) 721958‐74‐3
A Amlodipine Impurity‐D (EP) /Amlodipine Related Compound A (Aromatic Amlodipine/ Dehydro Amlodipine)
113994‐41‐5
1216406‐90‐4
A Amlodipine Impurity‐E (EP) /Amlodipine Related Compound E (Amlodipine Diethyl Ester)
140171‐65‐9
400024‐12‐6
A Amlodipine Impurity‐F (EP) /Amlodipine Related Compound F (Amlodipine Dimethyl Ester)
140171‐66‐0
400024‐11‐5
A Amlodipine Impurity‐G (EP) /Amlodipine Related Compound C 43067‐01‐2
A Amlodipine Impurity‐H (EP) ( 2‐Carboxybenzoyl Amlodipine) 318465‐73‐5
A Amlodipine 4‐Chloro Analogue (Para chloro Amlodipine) 90445‐02‐6
A Amlodipine Dimethoxy intermediate Impurity 140171‐50‐2
A Amlodipine Aspartic Acid Impurity 400602‐35‐9
A Amlodipine Lactose Adduct (Amlodipine N‐Lactoside) 749864‐27‐5
A Amlodipine Deschloro Impurity 88150‐52‐1
A Methyl benzenesulfonate 80‐18‐2
A ethyl benzenesulfonate 515‐46‐8
A Isopropyl Benzenesulfonate 6214‐18‐2
9.
A 4‐(2‐Phthalimidoethoxy)acetoacetic Acid Ethyl Ester 88150‐75‐8
A Ethyl 3‐aminocrotonate 626‐34‐6
A 5‐ethyl 7‐methyl 6‐(2‐chlorophenyl)‐8‐methyl‐3,4,6,7‐tetrahydro‐2H‐benzo[b][1,4]oxazine‐5,7‐dicarboxylate 496024‐43‐2
A
4‐(2‐Chlorophenyl)‐2,6‐bis[[2‐(1,3‐dihydro‐1,3‐dioxo‐2H‐isoindol‐2‐yl)ethoxy]methyl]‐1,4‐dihydro‐3,5‐
pyridinedicarboxylic Acid Ethyl Methyl Ester 223734‐99‐4
A 4‐[2‐(1,3‐Dihydro‐1,3‐dioxo‐2H‐isoindol‐2‐yl)ethoxy]‐3‐oxobutanoic Acid Methyl Ester 111429‐90‐4
A N‐(2‐Hydroxyethyl)phthalimide 3891‐07‐4
A Product: AMODIAQUINE IMPURITIES
A Amodiaquine Dichloro Impurity (Hydroxychloroquine EP Impurity G/ Chloroquine Related Compound A) 86‐98‐6
A N‐(4‐Hydroxyphenyl)acetamide 103‐90‐2
A Product: AMOXICILLIN IMPURITIES
A
Amoxicillin EP Impurity A/ Amoxicillin Related Compound A (Ampicillin EP Impurity A/ Cloxacillin EP Impurity C/
Flucloxacillin EP Impurity C/ Piperacillin EP Impurity H/ Sulbactam EP Impurity B/ 6‐Aminopenicillanic Acid) 551‐16‐6
A Amoxicillin EP Impurity B/ Amoxicillin Related Compound B (L‐Amoxicillin) 26889‐93‐0
A Amoxicillin EP Impurity C/ Amoxicillin Related Compound C (Amoxicillin Diketopiperazine) 94659‐47‐9
A Amoxicillin EP Impurity G/ Amoxicillin Related Compound G 188112‐75‐6
A Amoxicillin EP Impurity H/ Amoxicillin Related Compound H 205826‐86‐4
A Amoxicillin EP Impurity I/ Amoxicillin Related Compound I (Cefadroxil EP Impurity A/ Cefoperazone Impurity 3) 22818‐40‐2
A Amoxicillin EP Impurity J/ Amoxicillin Related Compound J (Amoxicillin Dimer) 73590‐06‐4
A Amoxicillin EP Impurity K 210289‐72‐8
A Amoxicillin EP Impurity L (6‐APA Amoxicillin Amide) 1789703‐32‐7
A Amoxicillin Trimer
174391‐69‐6
94703‐34‐1
A N‐Pivaloyl Amoxicillin 1313237‐94‐3
A Product: AMPICILLIN IMPURITIES
A
Ampicillin EP Impurity A (Amoxicillin EP Impurity A/ Amoxicillin Related Compound A/ Cloxacillin EP Impurity C/
Flucloxacillin EP Impurity C/ Piperacillin EP Impurity H/ Sulbactam EP Impurity B/ 6‐Aminopenicillanic Acid) 551‐16‐6
A Product: ANAGLIPTIN IMPURITIES
10.
A 2‐Methyl‐pyrazolo[1,5‐a]pyrimidine‐6‐carboxylic acid 739364‐95‐5
A 2‐(tert‐Butoxycarbonyloxyimino)phenylacetonitrile 58632‐95‐4
A (S)‐1‐(2‐Chloroacetyl)pyrrolidine‐2‐carbonitrile 207557‐35‐5
A 2‐Amino‐2‐methylpropanenitrile 19355‐69‐2
A Product: ANAGRELIDE IMPURITIES
A Anagrelide Related Compound A
85325‐12‐8
70406‐92‐7
A Anagrelide Related Compound B 1159977‐03‐3
A Anagrelide Related Compound C (Anagrelide open ring ethyl ester)
742010‐46‐4
70381‐75‐8
A Anagrelide open ring methyl ester 752151‐24‐9
A 2,3‐Dichloro‐6‐nitrobenzyl Alcohol 393078‐37‐0
A Product: ANASTROZOLE IMPURITIES
A Anastrozole EP Impurity A/ Anastrozole Related Compound B (α‐Desmethyl Anastrozole) 1215780‐15‐6
A Anastrozole EP Impurity B/ Anastrozole Related Compound C (Anastrozole Dimer Impurity) 1216898‐82‐6
A Anastrozole EP Impurity F (Lisinopril EP Impurity B, Tizanidine EP Impurity I, Sultamicillin EP Impurity B)
104‐15‐4
6192‐52‐5
A Anastrozole EP Impurity H/ Anastrozole Related Compound A 120511‐72‐0
A Anastrozole Monoacid 1338800‐82‐0
A 2,6‐di‐tert‐butyl‐4‐(2‐hydroxyethyl)phenol 3673‐68‐5
A Product: APIXABAN IMPURITIES
A Apixaban V 503614‐91‐3
A Apixaban m‐methoxy Analogue
A Apixaban o‐methoxy Analogue
A Apixaban ethoxy Analogue
A Apixaban Desmethoxy Analogue
A Apixaban Chloro Analogue
A Apixaban Dihydro pyridenone 545445‐44‐1
A Apixaban Carboxylic Acid Impurity 503614‐92‐4
A Apixaban 4,5‐Dehydro Carboxamide 1074549‐89‐5
11.
A Apixaban Amino Acid Impurity 1188385‐73‐0
A Apixaban Methyl Ester Impurity 1074365‐84‐6
A 1‐(4‐amino phenyl)‐3‐morpholino‐5,6‐dihydropyridin‐2 (1H)‐one 1267610‐26‐3
A Ethyl 2‐chloro‐2‐(2 ‐(4‐methoxyphenyl)hydrazono)acetate chloro ester 27143‐07‐3
A 1‐(4‐iodophenyl)‐3‐morpholino‐5,6‐dihydropyridin‐2(1H)‐one 473927‐69‐4
A Product: APREMILAST IMPURITIES
A Apremilast EP Impurity B (Apremilast 3‐Acetamido phthalic acid Impurity) 15371‐06‐9
A Apremilast EP Impurity H (Apremilast Des Acetamidophthalic acid Impurity) 253168‐94‐4
A Apremilast 2‐Acetamido Benzoic Acid Imurity 1809170‐71‐5
A Product: APREPITANT IMPURITIES
A Aprepitant Impurity C
A [1(S)‐Phenylethoxy]‐Aprepitant/ Aprepitant S,R,S‐Isomer 170902‐81‐5
A Product: ARIPIPRAZOLE IMPURITIES
A Aripiprazole EP Impurity A/ Aripiprazole Dihydroquinolinone Impurity 22246‐18‐0
A Aripiprazole EP Impurity B/ Aripiprazole Related Compound C
41202‐77‐1
119532‐26‐2
A Aripiprazole EP Impurity C (Aripiprazole 3‐Deschloro Impurity) 203395‐81‐7
A Aripiprazole EP Impurity D (Aripiprazole 2‐Deschloro Impurity) 203395‐82‐8
A Aripiprazole EP Impurity E/ Aripiprazole Related Compound G (Dehydro Aripiprazole) 129722‐25‐4
A Aripiprazole EP Impurity F/ Aripiprazole Related Compound F (Aripiprazole N‐Oxide) 573691‐09‐5
A Aripiprazole EP Impurity G (Aripiprazole Dimer) 1797986‐18‐5
A Aripiprazole Related Compound H 1796928‐63‐6
A Aripiprazole Hydroxybutylpiperazine Impurity 870765‐38‐1
A Aripiprazole Related Compound B (Aripiprazole Hydroxybutoxyquinoline Impurity) 889443‐20‐3
A Aripiprazole Diquinoline Butanediol Impurity 882880‐12‐8
A Aripiprazole N,N‐Dioxide 573691‐13‐1
A Aripiprazole Impurity‐1 21261‐76‐7
A Aripiprazole Impurity 2 1424857‐93‐1
12.
A Aripiprazole Bromo Impurity/ 7‐(4‐bromobutoxy)quinolin‐2(1H)‐one 203395‐59‐9
A Aripiprazole Quinolinone Impurity 70500‐72‐0
A Aripiprazole Chlorophenyl piperazine Impurity 65369‐76‐8
A Aripiprazole 3,4‐Dichloro Impurity 203395‐75‐9
A Aripiprazole Bromobutoxyquinoline Impurity 129722‐34‐5
A Aripiprazole 3,4‐Dichlorophenyl Piperazine
57260‐67‐0
76835‐17‐1
88138‐89‐0
A Aripiprazole 3,4‐Dichloro Impurity/ Aripiprazole 3,4‐Dichloro Analog
A Aripiprazole Butanoic Acid Impurity 58899‐27‐7
A Aripiprazole Desethylene Impurity 1216394‐63‐6
A Aripiprazole Iodobutoxyquinoline Impurity 952308‐47‐3
A Aripiprazole Methoxybutoxyquinoline Impurity 1770391‐64‐4
A Aripiprazole N‐Bromobutyl Impurity 1424857‐68‐0
A Aripiprazole N‐Isomer 1797983‐65‐3
A Aripiprazole Quinolinediol Impurity 1391054‐74‐2
A Chlorobutoxy Dihydroquinolinone 120004‐79‐7
A N1‐(2‐Chloroethyl)‐N2‐(2,3‐dichlorophenyl)ethane‐1,2‐diamine
A Di‐[2‐(2,3‐dichlorophenyl)aminoethyl]amine 1424857‐89‐5
A Bis (2,3‐Dichlorophenyl) piperazine
A 1,4‐Dibromobutane 110‐52‐1
A Product: ARMODAFINIL IMPURITIES
A Thiobenzhydrol 4237‐48‐3
A Product: ARTEMETHER IMPURITIES
A Artemether Ph. Int. Impurity A (Tricabonly compound) 1093625‐96‐7
A Artemether Related Compound A (Artemisinin Dihydro Impurity) 71939‐50‐9
A Artemether Related Compound B (α‐Artemether) 71939‐51‐0
A Product: ARTEMISININ IMPURITIES
A Artemisinin Dihydro Impurity (Artemether Related Compound A) 71939‐50‐9
A Product: ARTESUNATE IMPURITIES
13.
A Artesunate IP Impurity B (Artemisinin) 63968‐64‐9
A Product: ASCORBIC ACID IMPURITIES
A Ascorbic Acid EP Impurity C 16533‐48‐5
A Ascorbic Acid EP Impurity D 67776‐07‐2
A Ascorbic Acid EP Impurity E (Oxalic Acid) 144‐62‐7
A Product: ASENAPINE IMPURITIES
A Asenapine Tetradehydro Impurity 129385‐60‐0
A Asenapine N‐Desmethyl Impurity 1170701‐78‐6
A Asenapine N‐Oxide 128949‐51‐9
A rel‐(3aR,12bR)‐11‐Chloro‐2,3,3a,12b‐tetrahydro‐2‐methyl‐1H‐dibenz[2,3:6,7]oxepino[4,5‐c]pyrrol‐1‐one 129385‐59‐7
A N‐Desmethyl Asenapine
128915‐56‐0
1170701‐78‐6
A Product: ASPARTAME IMPURITIES
A Aspartame EP Impurity A/ Aspartame Related Compound A 5262‐10‐2
A Aspartame EP Impurity B/ Aspartame Related Compound B (Aspartame Acid) 13433‐09‐5
A Aspartame EP Impurity C (Nateglinide EP Impurity D)
150‐30‐1
63‐91‐2
A Product: ATAZANAVIR IMPURITIES
A Atazanavir Related Compund A (Methoxycarbonyl‐L‐tert‐leucine) 162537‐11‐3
A Atazanavir Related Compund D 4385‐62‐0
A Atazanavir Related Compund E 127406‐56‐8
A Atazanavir Impurity B/ 1‐Boc‐2‐[4‐(2‐pyridinyl)benzylidene]hydrazine 198904‐85‐7
A Atazanavir (3R,8S,9S,12S)‐Isomer (3‐Epi Atazanavir) 1332981‐14‐2
A Atazanavir (3S,8S,9S,12R)‐Isomer (12‐Epi Atazanavir) 1332981‐16‐4
A Atazanavir (3R,8S,9S,12R)‐Isomer 1292296‐11‐7
A Atazanavir (3R,8R,9S,12R)‐Isomer 1292296‐10‐6
A Atazanavir (3S,8R,9S,12S)‐Isomer (8‐epi Atazanavir) 1292296‐09‐3
A Atazanavir (3R,8R,9S,12S)‐Isomer
A Atazanavir (3S,8R,9S,12R)‐Isomer
A (2S,3S)‐3‐Boc‐amino‐1,2‐epoxy‐4‐phenylbutane 98737‐29‐2
14.
A (2R,3S)‐3‐(tert‐Boc)amino‐1,2‐epoxy‐4‐phenylbutane 98760‐08‐8
A Des‐N‐(methoxycarbonyl)‐L‐tert‐leucine Atazanavir Trihydrochloride 198904‐87‐9
A Product: ATENOLOL IMPURITIES
A Atenolol EP Impurity A 17194‐82‐0
A Atenolol EP Impurity B/ Atenolol Related Compound A 61698‐76‐8
A Atenolol EP Impurity C 29122‐69‐8
A Atenolol EP Impurity D 115538‐83‐5
A Atenolol EP Impurity E 141650‐31‐9
A Atenolol EP Impurity F/ Atenolol Related Compound D 87619‐83‐8
A Atenolol EP Impurity G/ Atenolol Related Compound C (Metoprolol Acid) 56392‐14‐4
A Atenolol EP Impurity H/ Atenolol Related Compound B 29277‐73‐4
A Atenolol EP Impurity I (Atenolol Desmethyl Impurity/ Atenolol Ethylamino Analog) 1797116‐92‐7
A Atenolol R‐Isomer 56715‐13‐0
A Atenolol S‐Isomer 93379‐54‐5
A Product: ATOMOXETINE IMPURITIES
A Atomoxetine EP Impurity A 873310‐33‐9
A Atomoxetine EP Impurity B (Atomoxetine S isomer) 82857‐39‐4
A Atomoxetine EP Impurity C/ Atomoxetine Related Compound C 873310‐31‐7
A Atomoxetine EP Impurity D/ Atomoxetine Related Compound B 873310‐28‐2
A Atomoxetine EP Impurity E (L‐Mandelic Acid/ (S)‐(+)‐Mandelic Acid) 17199‐29‐0
A Atomoxetine EP Impurity F 1010818‐92‐4
A Atomoxetine EP Impurity G
A Atomoxetine EP Impurity H/ Atomoxetine Related Compound A 42142‐52‐9
A Atomoxetine N‐Desmethyl Impurity 881995‐46‐6
A Destolyl Atomoxetine 115290‐81‐8
A 3‐(Methylamino)‐1‐phenylpropan‐1‐one Hydrochloride 2538‐50‐3
A (1S)‐3‐(Methylamino)‐1‐phenylpropan‐1‐ol) 114133‐37‐8
A 3‐(dimethylamino)‐1‐phenylpropan‐1‐one hydrochloride 3506‐36‐3
A 3‐Dimethylamino‐1‐phenyl‐1‐propanol 5554‐64‐3
A (S)‐3‐Dimethylamino‐3‐phenylpropanol 82769‐75‐3
15.
A 3‐chloro‐N,N‐dimethyl‐3‐phenylpropan‐1‐amine 79130‐51‐1
A Product: ATORVASTATIN IMPURITIES
A Atorvastatin EP Impurity A/ Atorvastatin Related Compound A (Desfluoro Atorvastatin)
433289‐83‐9
433289‐84‐0
A Atorvastatin EP Impurity C/ Atorvastatin Related Compound C (Atorvastatin Difluoro Analog)
693794‐20‐6
693793‐53‐2
A Atorvastatin EP Impurity D/ Atorvastatin Related Compound D (Atorvastatin Diketo Epoxide Impurity) 148146‐51‐4
A Atorvastatin EP Impurity E/ Atorvastatin Related Compound E
501121‐34‐2
1105067‐88‐6
A Atorvastatin EP Impurity F (Atorvastatin N‐(3,5‐Dihydroxy‐7‐heptanoic Acid)amide)
887196‐24‐9
1105067‐87‐5
1371615‐56‐3
A Atorvastatin EP Impurity G/ Atorvastatin Related Compound G (3‐O‐Methyl Atorvastatin) 887196‐29‐4
A Atorvastatin EP Impurity H/ Atorvastatin Related Compound H (Atorvastatin Lactone) 125995‐03‐1
A Atorvastatin EP Impurity I/ Atorvastatin Related Compound I (Atorvastatin Acetonide t‐Butyl Ester) 125971‐95‐1
A Atorvastatin Related Compound B (3‐epi‐Atorvastatin)
887196‐25‐0
887324‐52‐9
A Atorvastatin Diepoxide Lactone 1046118‐40‐4
A Atorvastatin Acetonide 581772‐29‐4
A
Atorvastatin Epoxy Pyrrolooxazin 7‐Hydroxy Analog (Atorvastatin FX1 Impurity/ Atorvastatin Cyclic Fluorophenyl
Impurity)
1315629‐79‐8
873950‐18‐6
A Atorvastatin Acid 134523‐00‐5
A Atorvastatin 3‐Deoxy‐Hept‐2‐Enoic Acid Sodium Salt (2,3‐Anhydro Atorvastatin/Dehydro Atorvastatin) 1105067‐93‐3
A Atorvastatin Oxirane Impurity 1246818‐88‐1
A Atorvastatin Methyl Ester 345891‐62‐5
A Atorvastatin Ethyl Ester 1146977‐93‐6
A Atorvastatin Acid tert‐Butyl Ester 134395‐00‐9
A
Atorvastatin Epoxy Tetrahydrofuran Analog (Atorvastatin Dihydroxy Epoxy Impurity/ Atorvastatin Degradation Product ‐
FXA2) 873950‐19‐7
16.
A Atorvastatin 3‐Oxo Impurity 1391052‐00‐8
A Atorvastatin 5‐Oxo Impurity 1391052‐82‐6
A Atorvastatin (3R,5S)‐isomer Impurity 131275‐93‐9
A Atorvastatin Olefin Impurity
A Atorvastatin Diketo Amide Impurity 125971‐96‐2
A
Atorvastatin FXA Impurity/ Atorvastatin Epoxy Pyrrolooxazin 6‐Hydroxy Analog/ Atorvastatin Cyclic Isopropyl Impurity/
Atorvastatin Cyclic 6‐Hydroxy Impurity
1316291‐19‐6
873950‐17‐5
A Dihydroxy Diketo Atorvastatin Impurity 1046118‐44‐8
A 2,3‐Anhydro Atorvastatin Lactone/ 3‐Dehydroxy 2,3‐Dehydro Atorvastatin Lactone/ Atorvastatin Eliminated Lactone 442851‐50‐5
A Butylhydroxyanisole
25013‐16‐5
121‐00‐6
A 2‐Hydroxy Atorvastatin
214217‐86‐4
265989‐46‐6
A 4‐Hydroxy Atorvastatin 265989‐44‐4
A (4R,cis)‐1,1‐Dimethylethyl‐6‐aminoethyl‐2,2‐dimethyl‐1,3‐dioxane‐4‐acetate 125995‐13‐3
A Product: ATOVAQUONE IMPURITIES
A Atovaquone EP Impurity A (Atovaquone Indene Isomer)
A Product: ATRACURIUM IMPURITIES
A 1,5‐Pentanediol diacrylate 36840‐85‐4
A Product: ATROPINE IMPURITIES
A Atropine EP Impurity A 500‐55‐0
A Product: AXITINIB IMPURITIES
A Axitinib Dimer 1428728‐84‐0
A 2,2'‐Dithiobis[N‐methyl‐benzamide] 2527‐58‐4
A Axitinib 2‐Mercapto N‐Methyl Benzamide 20054‐45‐9
A Product: AZACITIDINE IMPURITIES
A Azacitidine Related Compound A (5‐Aza Cytosine/ Decitabine Triazinone Impurity) 931‐86‐2
A Product: AZACYTIDINE IMPURITIES
A (5‐O‐Acetyl‐β‐D‐ribofuranosyl)‐Azacytidine 1174733‐90‐4
A Product: AZATHIOPRINE IMPURITIES
17.
A Azathioprine EP Impurity A/ Azathioprine Related Compound A (Thiamiprine) 4531‐54‐8
A Azathioprine EP Impurity B 157930‐13‐7
A Azathioprine EP Impurity C 4897‐25‐0
A Azathioprine EP Impurity D 6339‐54‐4
A Azathioprine EP Impurity E
73703‐74‐9
35681‐68‐6
A Azathioprine EP Impurity F (Didanosine EP Impurity A/ Didanosine Related Compound A/ Hypoxanthine) 68‐94‐0
A Azathioprine EP Impurity G/ Azathioprine Related Compound G (Thiamiprine) 5581‐52‐2
A Product: AZELASTINE IMPURITIES
A Azelastine EP Impurity A (Benzohydrazide) 613‐94‐5
A Azelastine EP Impurity B/ Azelastine Related Compound B
110406‐94‐5
117078‐69‐0
A Azelastine EP Impurity C 53242‐76‐5
A Azelastine EP Impurity D 53242‐89‐9
A Azelastine EP Impurity E/ Azelastine Related Compound E 20526‐97‐0
A Product: AZILSARTAN IMPURITIES
A Azilsartan Impurity A/ Azilsartan Methyl Ester Amide Impurity 147404‐76‐0
A Azilsartan Impurity C 1397836‐49‐5
A Azilsartan Impurity H 1499167‐72‐4
A Azilsartan Impurity I/ Azilsartan O‐Desethyl Nitrile Impurity 139481‐33‐7
A Azilsartan Impurity J 1403474‐78‐1
A Azilsartan Impurity M 632322‐61‐3
A Azilsartan Methyl Ester 147403‐52‐9
A Azilsartan Diamino Impurity 136285‐69‐3
A Desethyl Azilsartan Medoxomil 1417576‐00‐1
A 1‐[(2’‐Cyano‐1,1’‐biphenyl‐4‐yl)methyl]‐2‐ethoxy‐7‐benzimidazolecarboxylic Acid Methyl Ester 139481‐44‐0
A Methyl 2‐Ethoxy‐1‐[[2’‐(hydroxyamidino)biphenyl‐4‐yl]methyl]‐1H‐benzimidazole‐7‐carboxylate 147403‐65‐4
18.
A
(2‐oxo‐1,3‐dioxole‐4,5‐diyl)bis(methylene) bis(2‐ethoxy‐1‐((2'‐(5‐oxo‐4,5‐dihydro‐1,2,4‐oxadiazol‐3‐yl)‐[1,1'‐biphenyl]‐
4‐yl)methyl)‐1H‐benzo[d]imidazole‐7‐carboxylate) 1417576‐02‐3
A Product: AZITHROMYCIN IMPURITIES
A
Azithromycin EP Impurity A (N6‐Demethylazithromycin/ Desmethylazithromycin/ 9‐Deoxo‐9a‐aza‐9a‐homo
Erythromycin A/ Azaerythromycin A/ Azathramycin) 76801‐85‐9
A Azithromycin EP Impurity B (3‐Deoxyazithromycin/ 3‐Deshydroxy Azithromycin) 307974‐61‐4
A Azithromycin EP Impurity C (3‐O‐Demethyl Azithromycin) 620169‐47‐3
A Azithromycin EP Impurity E (Amino Azithromycin/ 3′‐(N,N‐Didemethyl)azithromycin) 612069‐27‐9
A Azithromycin EP Impurity F/ Azithromycin Related Compound F (3′‐N‐Demethyl‐3′‐N‐formylazithromycin) 612069‐28‐0
A Azithromycin EP Impurity G (3′‐N‐Demethyl‐3′‐N‐[(4‐methylphenyl)sulfonyl]azithromycin) 612069‐31‐5
A
Azithromycin EP Impurity H/ Azithromycin Related Compound H (3′‐N‐[[4‐(Acetylamino)phenyl]sulfonyl]‐3′‐N‐
demethylazithromycin) 612069‐30‐4
A Azithromycin EP Impurity I/ N‐Demethylazithromycin (3′‐N‐Demethyl Azithromycin) 172617‐84‐4
A Azithromycin EP Impurity J/ Desosaminylazithromycin (13‐O‐Decladinosylazithromycin/ Descladinose Azithromycin) 117693‐41‐1
A Azithromycin EP Impurity L/ Azithromycin N‐Oxide (Azithromycin 3‐N‐Oxide) 90503‐06‐3
A Azithromycin EP Impurity M (3′‐(N,N‐Didemethyl)‐3′‐N‐formylazithromycin) 765927‐71‐7
A Azithromycin EP Impurity N (3′‐De(Dimethylamino)‐3′‐oxoazithromycin/ 3‐Des(dimethylamino)‐3‐keto Azithromycin) 612069‐25‐7
A Azithromycin Impurity R (Erythromycin A 9,11‐Imino Ether) 161193‐44‐8
A
Azithromycin Impurity S (9‐Erythromycin A Oxime/ Erythromycin Oxime/ Roxithromycin Impurity C/ Clarithromycin EP
Impurity J) 13127‐18‐9
A Azithromycin Iminoether impurity (Erythromycin A 6,9‐Imino Ether) 99290‐97‐8
A Hydroxy Azithromycin 756825‐20‐4
B Product: BACLOFEN IMPURITIES
B Baclofen EP Impurity A 22518‐27‐0
B Baclofen EP Impurity B 1141‐23‐7
B Baclofen Impurity 1 35271‐74‐0
B Chlorophenylglutaric acid anhydride 53911‐68‐5
B 4‐(4‐Chlorophenyl)‐2,6‐piperidinedione 84803‐46‐3
B 2‐(4‐Chlorophenyl)‐4‐hydroxy‐4‐methyl‐6‐oxo‐1,3‐Cyclohexanedicarboxylic Acid Diethyl Ester 294194‐13‐1
B Butyl 4‐amino‐3‐(p‐chlorophenyl)butyrate
B 4‐Amino‐3‐(3,4‐dichlorophenyl)butyric acid
19.
B Dibaclofen Urea (N,N‐Di[3‐carboxy‐2‐(4‐chlorophenyl)‐propyl]urea)
B
Dibaclofen Urea Mono Lactum (3‐(p‐Chlorophenyl)‐4‐{[4‐(p‐chlorophenyl)‐2‐oxo‐1‐pyrrolidinyl]carbonylamino}butyric
acid)
B Product: BALSALAZIDE IMPURITIES
B Balsalazide Related Compound A
1242567‐07‐2
1398634‐47‐3
B Balsalazide Related Compound B 1242567‐09‐4
B Balsalazide Isopropyl Ester 1346606‐13‐0
B Balsalazide Aminobenzoyl Impurity 7377‐08‐4
B Product: BAZEDOXIFENE IMPURITIES
B Bazedoxifene N‐Oxide 1174289‐22‐5
B Product: BECLOMETASONE IMPURITIES
B Beclometasone Dipropionate EP Impurity R 981‐34‐0
B Beclometasone Dipropionate EP Impurity V (Betamethasone 9,11‐Epoxide 21‐Propionate) 205105‐83‐5
B Product: BENAZEPRIL IMPURITIES
B Benazepril EP Impurity C/ Benazepril Related Compund C (Benazeprilat) 86541‐78‐8
B Benazepril EP Impurity D/ Benazepril Related Compund D
B Benazepril EP Impurity E/ Benazepril Related Compund E
88372‐47‐8
2013‐07‐05
B Benazepril EP Impurity F/ Benazepril Related Compund F 109010‐60‐8
B Benazepril EP Impurity G/ Benazepril Related Compund G (Benazepril Ethyl Ester) 103129‐58‐4
B Product: BENDAMUSTINE IMPURITIES
B Bendamustine Related Compound A (Bendamustine Dihydroxy Impurity) 109882‐30‐6
B Bendamustine Related Compound E (Bendamustine Monohydroxy Acid Impurity) 109882‐27‐1
B Bendamustine Related Compound G (Bendamustine Impurity D/ Bendamustine Thiazine Impurity) 191939‐34‐1
B Bendamustine Related Compound H (Bendamustine Trichloroethyl Dimer Impurity) 1228551‐91‐4
B Bendamustine Methyl Ester 109882‐25‐9
B Bendamustine Hydrochloride ‐ In house impurity 109882‐31‐7
B Bendamustine Dideschloroethyl Acid Impurity 914626‐62‐3
B Bendamustine Isopropyl Ester 1313020‐25‐5
20.
B Deschloroethyl Bendamustine
1219709‐86‐0
1797881‐48‐1
B Bendamustine Deschloro Dimer Impurity/ Bendamustine Trihydroxyethyl Dimer Impurity 1391052‐61‐1
B N1‐Methylbenzene‐1,2,4‐triamine hydrochloride 60651‐29‐8
B Bendamustine Dideschloroethyl Ethyl Ester 3543‐73‐5
B Product: BENOXACOR IMPURITIES
B 2,2‐dichloro‐N‐[2‐(hydroxypropoxy)phenyl]acetamide
B Product: BENZOTHIADIAZINE IMPURITIES
B
Benzothiadiazine Related Compound A (Hydrochlorothiazide EP Impurity B/ Hydrochlorothiazide Related Compound A/
Salamide/ Altizide EP Impurity A) 121‐30‐2
B Product: BENZYDAMINE IMPURITIES
B Benzydamine EP Impurity C 2215‐63‐6
B Product: BESIFLOXACIN IMPURITIES
B Besifloxacin Impurity B 101987‐89‐7
B Besifloxacin Impurity G/ (R)‐3‐Amino‐hexahydroazepine/ Besifloxacin (R)‐Azepan‐3‐Amine Impurity 124932‐43‐0
B Besifloxacin (3S)‐Isomer 141388‐77‐4
B (3R)‐3‐Aminoazepane‐1‐carboxylic Acid tert‐Butyl Ester 1032684‐85‐7
B Boc‐L‐serine 3262‐72‐4
B Product: BETAHISTINE IMPURITIES
B Betahistine EP Impurity A 100‐69‐6
B Betahistine EP Impurity B 103‐74‐2
B Betahistine EP Impurity C
2095467‐43‐7
5452‐87‐9
B 2‐Pyridyl acetic Acid 13115‐43‐0
B Product: BETAMETHASONE IMPURITIES
B Betamethasone Dipropionate EP Impurity A 378‐44‐9
B Betamethasone Dipropionate Impurity B (EP)/ Clobetasol Propionate Impurity‐A (EP) (Betamethasone 17‐Propionate) 5534‐13‐4
B Betamethasone Dipropionate Impurity C (EP)/ Clobetasol Propionate Impurity‐K (EP) (Betamethasone 21‐Propionate) 75883‐07‐7
21.
B Betamethasone Dipropionate EP Impurity G (Betamethasone Tripropionate) 1186048‐33‐8
B Betamethasone Impurity B (EP)/ Clobetasol Propionate Impurity‐G (EP) 25122‐41‐2
B Betamethasone Acetate EP Impurity B (Dexamethasone EP Impurity G/ 21‐O‐Acetyl Dexamethasone) 1177‐87‐3
B Betamethasone 9,11‐Epoxide 21‐Propionate (Beclometasone Dipropionate EP Impurity V) 205105‐83‐5
B Betamethasone Valerate 2152‐44‐5
B Product: BETAXOLOL IMPURITIES
B Betaxolol EP Impurity A
67193‐95‐7
464877‐45‐0
B Product: BEZAFIBRATE IMPURITIES
B Bezafibrate EP Impurity B (Acemetacin EP Impurity A/ Indomethacin EP Impurity A/ Indomethacin Related Compound B) 74‐11‐3
B Product: BICALUTAMIDE IMPURITIES
B Bicalutamide EP Impurity A (Desfluoro Bicalutamide) 90357‐05‐4
B Bicalutamide EP Impurity B (Bicalutamide 2‐Fluoro Isomer) 1159977‐36‐2
B Bicalutamide EP Impurity C (Bicalutamide Deshydroxy Impurity) 906008‐94‐4
B Bicalutamide EP Impurity D 654‐70‐6
B Bicalutamide EP Impurity H
B Bicalutamide EP Impurity J (Bicalutamide Sulfide) 90356‐78‐8
B Bicalutamide EP Impurity K & L
B Bicalutamide Related Compound B (Bicalutamide 3‐Fluoro Isomer) 1166228‐30‐3
B Product: BIFONAZOLE IMPURITIES
B Bifonazole EP Impurity C (Clotrimazole EP Impurity D/ Enalapril EP Impurity I/ Ondansetron EP Impurity E/ Imidazole) 288‐32‐4
B Product: BIMATOPROST IMPURITIES
B Bimatoprost Acid 38344‐08‐0
B 15‐Keto Bimatoprost 1163135‐96‐3
B Bimatoprost Acid Methyl Ester 38315‐47‐8
B 5,6‐Trans Bimatoprost 1163135‐95‐2
B 15‐epi Bimatoprost 1163135‐92‐9
B Bimatoprost isopropyl ester 130273‐87‐9
B Product: BISACODYL IMPURITIES
22.
B Bisacodyl EP Impurity A/ Bisacodyl Related Compound A 603‐41‐8
B Bisacodyl EP Impurity C/ Bisacodyl Related Compound C 72901‐16‐7
B Product: BISOPROLOL IMPURITIES
B Bisoprolol EP Impurity A (Des(isopropoxyethyl) Bisoprolol) 62572‐93‐4
B Bisoprolol EP Impurity B (Bisoprolol Propyl Analog) 1447715‐44‐7
B Bisoprolol EP Impurity G 1215342‐36‐1
B Bisoprolol EP Impurity K (Bisoprolol Ester Impurity)
1346603‐26‐6
864544‐37‐6
B Bisoprolol EP Impurity L 29122‐74‐5
B Bisoprolol EP Impurity M 177034‐57‐0
B Bisoprolol EP Impurity N 1346601‐75‐9
B Bisoprolol EP Impurity Q 1346604‐00‐9
B Bisoprolol EP Impurity S (4‐Hydroxybenzaldehyde) 123‐08‐0
B Bisoprolol Carboxylic Acid Impurity 72570‐70‐8
B Bisoprolol Dimer
B N‐Formyl Bisoprolol 1447715‐45‐8
B Bisoprolol Impurity 1 1346603‐05‐1
B 4‐(2,3‐Epoxypropoxy)benzaldehyde 14697‐49‐5
B 1,1'‐[Methylenebis(4,1‐phenyleneoxy)]bis[3‐[(1‐methylethyl)amino]‐2‐propanol 1225195‐70‐9
B Product: BLONANSERIN IMPURITIES
B Desfluoro Blonanserin 132810‐75‐4
B Chloro Blonanserin
B Methoxy Blonanserin
B N‐Methyl Blonanserin
B Desethyl Blonanserin 132811‐84‐8
B Blonanserin Impurity 3672‐47‐7
B Blonanserin Impurity 4640‐66‐8
B Blonanserin Impurity 614‐16‐4
B Product: BORTEZOMIB IMPURITIES
23.
B Bortezomib Related Compound A/ Bortezomib Impurity D (Bortezomib R,R‐Isomer Impurity) 1132709‐15‐9
B Bortezomib Related Compund B/ Bortezomib Amide Analog 289472‐80‐6
B Bortezomib Related Compund D/ Bortezomib Acid Analog 114457‐94‐2
B Bortezomib Related Compound G (Bortezomib S,S‐Isomer Impurity) 1132709‐14‐8
B
Bortezomib Related Compund I/ (S,R)‐Bortezomib Hydroxyisopentyl Amide Analog (Bortezomib Hydroxy S,R‐Isomer
Impurity) 289472‐78‐2
B
Bortezomib Related Compund J/ (S,S)‐Bortezomib Hydroxyisopentyl Amide Analog (Bortezomib Hydroxy S,S‐Isomer
Impurity) 289472‐81‐7
B Bortezomib Impurity F/ Bortezomib Acid Methyl Ester 73058‐37‐4
B Bortezomib Impurity H 1446194‐56‐4
B Bortezomib S,R‐Isomer Impurity 1132709‐16‐0
B Bortezomib Amino R Isomer 179324‐87‐9
B Bortezomib Pinanediol Impurity 205393‐22‐2
B Product: BOSENTAN IMPURITIES
B Bosentan Related Compound A 150727‐06‐3
B Bosentan Related Compound B (O‐Deshydroxyethyl Bosentan) 174227‐14‐6
B Bosentan Related Compound C 1097263‐60‐9
B Bosentan Related Compound D 150728‐13‐5
B Bosentan Related Compound E 6292‐59‐7
B 4‐Chloro‐6‐[2‐(1,1‐dimethylethoxy)ethoxy]‐5‐(2‐methoxyphenoxy)‐2,2'‐bipyrimidine 1177447‐87‐8
B Product: BREXPIPRAZOLE IMPURITIES
B Brexpiprazole 5‐1H‐Quinolin‐2‐one 2116542‐20‐0
B Brexpiprazole (3,4)‐Dihydro‐2(1H)‐quinolinone 913612‐07‐4
B Brexpiprazole N‐Oxide 1191900‐58‐9
B Brexpiprazole Sulfoxide 1191900‐51‐2
B 7‐(4‐bromobutoxy)quinolin‐2(1H)‐one/ Aripiprazole Bromo Impurity 203395‐59‐9
B 7‐(4‐Hydroxybutoxy)‐2(1H)‐quinolinone 1886188‐97‐1
B N‐(3‐hydroxyphenyl)cinnamamide 616227‐75‐9
B N‐(3‐methoxyphenyl)cinnamamide 15116‐41‐3
24.
B 5‐hydroxyquinolin‐2(1H)‐one 31570‐97‐5
B 1,4‐Bis(benzo[b]thien‐4‐yl)piperazine 1420987‐86‐5
B
7‐(4‐(4‐(benzo[b]thiophen‐4‐yl)piperazin‐1‐yl)butoxy)‐1‐(4‐((2‐oxo‐1,2‐dihydroquinolin‐7‐yl)oxy)butyl)quinolin‐2(1H)‐
one 2094559‐58‐5
B Piperazine‐1‐(4‐benzofuranyl) hydrochloride 105684‐85‐3
B 7‐(4‐(4‐(benzofuran‐4‐yl)piperazin‐1‐yl)butoxy)quinolin‐2(1H)‐one
B 1‐([2,4'‐bibenzo[b]thiophen]‐4‐yl)piperazine 2126178‐13‐8
B 7‐(4‐(4‐([2,4'‐bibenzo[b]thiophen]‐4‐yl)piperazin‐1‐yl)butoxy)quinolin‐2(1H)‐one
B 7,7'‐[(1,4‐Butanediyl)bis(oxy)]bis‐2(1H)quinolinone 2116542‐19‐7
B 1‐(4‐(4‐(benzo[b]thiophen‐4‐yl)piperazin‐1‐yl)butyl)‐7‐hydroxyquinolin‐2(1H)‐one
B
1‐(4‐(4‐(benzo[b]thiophen‐4‐yl)piperazin‐1‐yl)butyl)‐7‐(4‐((2‐oxo‐1,2‐dihydroquinolin‐7‐yl)oxy)butoxy)quinolin‐2(1H)‐
one
B 7‐(4‐(4‐(2,3‐dihydro‐[2,4'‐bibenzo[b]thiophen]‐4‐yl)piperazin‐1‐yl)butoxy)quinolin‐2(1H)‐one
B 7‐(4‐Chlorobutoxy)‐1‐(4‐chlorobutyl)quinolin‐2‐one 2059954‐32‐2
B 1,4‐bis(4‐(benzo[b]thiophen‐4‐yl)piperazin‐1‐yl)butane
B 1‐(Benzo[b]thiophen‐4‐yl)‐4‐(4‐((2‐oxo‐l,2‐dihydroquinolin‐7‐yl)oxy)butyl) piperazine 1,4‐dioxide
B 1‐(2,3‐dihydro‐[2,4'‐bibenzo[b]thiophen]‐4‐yl)piperazine 1420987‐85‐4
B 1‐(benzo[b]thiophen‐4‐yl)‐4‐(4‐((2‐oxo‐1,2,3,4‐tetrahydroquinolin‐7‐yl)oxy)butyl)piperazine 1,4‐dioxide
B 1‐(benzo[b]thiophen‐4‐yl)piperazine 846038‐18‐4
B 7‐(4‐(piperzin‐1‐yl)butoxy)quinolin‐2(1H)‐one 1849603‐58‐2
B 7,7'‐((piperazine‐1,4‐diylbis(butane‐4,1‐diyl))bis(oxy))bis(quinolin‐2(1H)‐one) 2220149‐92‐6
B 4‐Bromo benzo[b]thiophene 5118‐13‐8
B 7‐(4‐chloro butoxy)‐1H‐quinolin‐2‐one 913613‐82‐8
B Benzo thiophene 95‐15‐8
B Product: BRIMONIDINE IMPURITIES
B Brimonidine EP Impurity A (Desbromo Brimonidine) 91147‐43‐2
B Brimonidine EP Impurity B/ Brimonidine Related Compound A 50358‐63‐9
B Brimonidine EP Impurity C (Quinoxalin‐6‐amine) 6298‐37‐9
B Product: BRINZOLAMIDE IMPURITIES
B Desmethyl Brinzolamide 186377‐56‐0
B Brinzolamide methanesulfonyl Impurity
25.
B Product: BRIVUDINE IMPURITIES
B Beta‐(Z)‐Brivudine (β‐(Z)‐Brivudine)
B Product: BROMFENAC IMPURITIES
B Bromfenac Lactam 91713‐91‐6
B 2‐Amino‐3‐(4‐bromobenzoyl)benzoic Acid 241496‐82‐2
B 7‐(4‐Bromobenzoyl)‐1H‐indole‐2,3‐dione 241825‐88‐7
B 2‐Amino‐3‐(4‐bromobenzoyl)phenyloxoacetic Acid
1391052‐54‐2
241825‐87‐6
B 2‐Amino‐3‐benzoyl‐α‐oxo‐benzeneacetic Acid 126849‐31‐8
B 7‐Benzoylindoline‐2,3‐dione 70803‐94‐0
B Product: BROMHEXINE IMPURITIES
B Bromhexine EP Impurity A (Ambroxol EP Impurity A) 50739‐76‐9
B Bromhexine EP Impurity B (Ambroxol EP Impurity E) 50910‐55‐9
B Product: BRONOPOL IMPURITIES
B Tris(hydroxymethyl)nitromethane 126‐11‐4
B 2‐Methyl‐2‐nitro‐1,3‐propanediol 77‐49‐6
B Product: BUDESONIDE IMPURITIES
B Budesonide EP Impurity‐A 13951‐70‐7
B Budesonide EP Impurity‐B (Budesonide Acetylaldehyde Acetal) 1040085‐98‐0
B Budesonide EP Impurity‐D (Budesonide Aldehyde Impurity) 85234‐63‐5
B Budesonide EP Impurity‐E/ Budesonide Related Compund E(14,15‐Dehydro Budesonide) 131918‐64‐4
B Budesonide EP Impurity‐F (Desonide) 638‐94‐8
B Budesonide EP Impurity‐I (16α‐Butyloxy Prednisolone) 113930‐13‐5
B Budesonide EP Impurity‐K (Budesonide 21‐Acetate) 51333‐05‐2
B Budesonide EP Impurity‐L/ Budesonide Related Compund L(11‐Keto Budesonide) 216453‐74‐6
B Product: BUMETANIDE IMPURITIES
B Bumetanide EP Impurity A/ Bumetanide Related Compound B 28328‐53‐2
B Bumetanide EP Impurity B/ Bumetanide Related Compound A (Desbutyl Bumetanide) 28328‐54‐3
B Bumetanide EP Impurity C (Bumetanide Butyl Ester) 32643‐00‐8
26.
B Bumetanide EP Impurity D 153012‐65‐8
B Bumetanide Impurity 1 22892‐96‐2
B Bumetanide Impurity 67155‐14‐0
B Bumetanide Impurity 56106‐57‐1
B N‐Desbutyl‐N‐propyl Bumetanide 28395‐28‐0
B Product: BUPIVACAINE IMPURITIES
B Bupivacaine EP Impurity A (Mepivacaine EP Impurity C) 39627‐98‐0
B Bupivacaine EP Impurity B/ Bupivacaine Related Compound B (Mepivacaine EP Impurity B/ N‐Desbutyl Bupivacaine)
15883‐20‐2
65797‐42‐4
B Bupivacaine EP Impurity E/ Bupivacaine Related Compound A 1330172‐81‐0
B
Bupivacaine EP Impurity F (Lidocaine EP Impurity A/ Lidocaine Related Compound A/ Ropivacaine EP Impurity H/
Ropivacaine Related Compound A/ Mepivacaine EP Impurity A)
87‐62‐7
21436‐98‐6
B 1‐(2,6‐Dimethylphenyl)azepan‐2‐one (Cyclised Impurity)
B 4‐Hexylbenzene‐1,3‐diol 136‐77‐6
B 1‐(2,4‐Dihydroxyphenyl)hexan‐1‐one 3144‐54‐5
B 4‐pentylbenzene‐1,3‐diol 533‐24‐4
B 1‐(2,4‐dihydroxyphenyl)pentan‐1‐one 15116‐13‐9
B Product: BUPROPION IMPURITIES
B Bupropion Related Compound A 1049718‐72‐0
B Bupropion Related Compound B 1049718‐43‐5
B Bupropion Related Compound C 152943‐33‐4
B Bupropion Related Compound D (Deschloro Bupropion)
63199‐74‐6
34509‐36‐9
B Bupropion Related Compound E 10557‐17‐2
B Bupropion Related Compound F 857233‐13‐7
B (3S,5R,6R)‐Bupropion Impurity 2133460‐43‐0
B Bupropion Des‐t‐tbutylamine Impurity (3’‐Chloropropiophenone) 936‐59‐4
B Bupropion 2‐Bromo Impurity 34911‐51‐8
B Bupropion Amino Impurity 119802‐69‐6
27.
B Bupropion 3,4‐Dichloro Impurity 1193779‐34‐8
B Bupropion Des‐t‐Butylamino Impurity 34841‐35‐5
B Bupropion 2‐Chloro Analog 1049718‐57‐1
B Bupropion 3,5‐Dichloro Impurity 1193779‐48‐4
B Product: BUSPIRONE IMPURITIES
B Buspirone EP Impurity A/ Buspirone Related Compound A 20980‐22‐7
B Buspirone EP Impurity B 81461‐73‐6
B Buspirone EP Impurity C/ Buspirone Bispyrimidinylpiperazinyl Butane Impurity 257877‐45‐5
B Buspirone EP Impurity D/ Buspirone Bispyrimidinylpiperazinylbutyl Ether Impurity
B Buspirone EP Impurity E/ Buspirone Open Ring Impurity 257877‐46‐6
B Buspirone EP Impurity F/ Buspirone Open‐Ring Dimer Impurity
B Buspirone EP Impurity G/ Buspirone Related Compound G 84746‐24‐7
B Buspirone EP Impurity H/ Buspirone Diester Dimer
B Buspirone EP Impurity I/ 5‐Chloro Buspirone
B Buspirone EP Impurity J/ Buspirone Open Ring Spirodimer Impurity
B Buspirone EP Impurity K/ Buspirone Related Compound K 1075‐89‐4
B Buspirone EP Impurity L/ Buspirone Related Compund L 21098‐11‐3
B Buspirone EP Impurity M/ Buspirone Bromobutyl Impurity 80827‐62‐9
B Buspirone EP Impurity N/ Buspirone Related Compund N 257877‐44‐4
B Buspirone N‐Oxide 220747‐81‐9
B Buspirone 5‐Hydroxy Metabolite 105496‐33‐1
B Buspirone 6‐Hydroxy Metabolite 125481‐61‐0
B Product: BUSULFAN IMPURITIES
B Busulfan Methylsulfinyloxy Analog 106‐48‐9
B Product: BUTANILICAINE IMPURITIES
B 2,2'‐Dichloro‐6'‐methylacetanilide 6307‐67‐1
C Product: CAFFEINE IMPURITIES
C
Caffeine EP Impurity A (Theophylline/ Diprophylline EP Impurity B/ Dimenhydrinate EP Impurity A/ Pentoxifylline EP
Impurity C) 58‐55‐9
C Caffeine EP Impurity C 519‐32‐4
28.
C Caffeine EP Impurity F (Paraxanthine) 611‐59‐6
C 1‐Methyl‐1H‐imidazole‐5‐carboxylic acid 41806‐40‐0
C Product: CANAGLIFLOZIN IMPURITIES
C Cangliflozin Furanose impurity
C Methoxy Canagliflozin 1358581‐37‐9
C Canagliflozin Desfluoro Impurity 842133‐16‐8
C Canagliflozin Monoacetyl Impurity 2146135‐87‐5
C Canagliflozin Bromo Impurity 1030825‐20‐7
C 2‐(4‐Fluorophenyl)‐thiophene 58861‐48‐6
C
(5‐(4‐fluorophenyl)thiophen‐2‐yl)(2‐methyl‐5‐(3,4,5‐trihydroxy‐6‐(hydroxymethyl)tetrahydro‐2H‐pyran‐2‐
yl)phenyl)methanone 1951467‐28‐9
C 3‐Iodo‐2‐methylbenzoic acid 133232‐56‐1
C Product: CANDESARTAN IMPURITIES
C Candesartan Cilexetil EP Impurity A (Candesartan Ethyl Ester) 139481‐58‐6
C Candesartan Cilexetil EP Impurity B (Candesartan Cilexetil O‐Desethyl Analog) 869631‐11‐8
C Candesartan Cilexetil EP Impurity C (Candesartan Cilexetil N1‐Ethyl Amide) 1185255‐99‐5
C Candesartan Cilexetil EP Impurity D (Candesartan Cilexetil N2‐Ethyl Amide) 1185256‐03‐4
C Candesartan Cilexetil EP Impurity E (Candesartan Cilexetil N1‐Ethyl Analog) 914613‐35‐7
C Candesartan Cilexetil EP Impurity F (Candesartan Cilexetil N2‐Ethyl Impurity) 914613‐36‐8
C Candesartan Cilexetil EP Impurity G (Candesartan Acid) 139481‐59‐7
C Candesartan Cilexetil EP Impurity H (N1‐Trityl Candesartan Cilexetil) 170791‐09‐0
C Candesartan Cilexetil EP Impurity I (Candesartan Methyl Ester) 139481‐69‐9
C Candesartan Benzimidazole Ethoxy Methyl Ester 150058‐27‐8
C Candesartan Benzimidazole Methoxy Methyl Ester/ Candesartan Benzimidazole Methoxy Impurity 1246817‐06‐0
C Candesartan Bromo N1‐Trityl Impurity 124750‐51‐2
C
Candesartan Trityl Alcohol Impurity (Losartan EP Impurity G/ Triphenylmethanol/ Trityl Alcohol/ Irbesartan
Triphenylmethanol Impurity/ Zidovudine EP Impurity D) 76‐84‐6
C Candesartan Acid Methoxy Analog 139481‐76‐8
C O‐Desethyl Candesartan 168434‐02‐4
C Candesartan N1‐Cilexetil Ethyl Ester/ Candesartan Ethyl Ester N1‐Cilexetil Analog 1391054‐45‐7
29.
C Candesartan Hydroxy Impurity (Irbesartan Hydroxy Impurity/ Losartan Hydroxy Impurity/ Losartan EP Impurity B) 160514‐13‐6
C
Candesartan Dibromo N2‐Trityl Impurity/ Candesartan Dibromo TTBB Impurity (Irbesartan Dibromo N2‐Trityl Impurity/
Losartan Dibromo N2‐Trityl Impurity/ Olmesartan Dibromo N2‐Trityl Impurity/ Valsartan Dibromo N2‐Trityl Impurity) 151052‐34‐5
C
Candesartan Methyl Impurity (Losartan EP Impurity E/ Losartan Methyl Impurity/ Irbesartan EP Impurity E/ Irbesartan
Methyl Impurity) 120568‐11‐8
C Candesartan Nitro Impurity 136285‐67‐1
C 3‐Aminophthalic Acid 5434‐20‐8
C Product: CAPECITABINE IMPURITIES
C Capecitabine EP Impurity A/ Capecitabine Related Compund A 66335‐38‐4
C Capecitabine EP Impurity B/ Capecitabine Related Compund B (Doxifluridine/ Deoxy‐5‐fluorouridine) 3094‐09‐5
C Capecitabine EP Impurity F/ Capecitabine Related Compund C (2,3‐O‐Carbonyl‐Capecitabine) 921769‐65‐5
C Capecitabine Related Compund I (3'‐O‐(5'‐Deoxy‐α‐D‐ribofuranosyl) Capecitabine) 1262133‐68‐5
C Product: CAPTOPRIL IMPURITIES
C Captopril EP Impurity A (Captopril disulphide) 64806‐05‐9
C Captopril EP Impurity C 26473‐47‐2
C Product: CARBAMAZEPINE IMPURITIES
C Carbamazepine EP Impurity A/ Carbamazepine Related Compound A 3564‐73‐6
C Carbamazepine EP Impurity B/ Carbamazepine Related Compound D (9‐methylacridine) 611‐64‐3
C Carbamazepine EP Impurity C/ Carbamazepine Related Compound C 1219170‐51‐0
C Carbamazepine EP Impurity D/ Carbamazepine Related Compound B (Oxcarbazepine EP Impurity E/ Iminostilbene) 256‐96‐2
C Carbamazepine EP Impurity E (Iminobibenzyl/ Trimipramine EP Impurity F/ Clomipramine EP Impurity E) 494‐19‐9
C Carbamazepine EP Impurity F/ Carbamazepine Related Compound F 33948‐22‐0
C Carbamazepine Dihydro Chlorocarbonyl Impurity (IDBCC) 33948‐19‐5
30.
C Carbamazepine 10,11‐Epoxide 36507‐30‐9
C Product: CARBIDOPA IMPURITIES
C Carbidopa EP Impurity A (Methyldopa) 41372‐08‐1
C Carbidopa EP Impurity B (α‐Methyldopa Methyl Ester) 18181‐08‐3
C Carbidopa EP Impurity G 2503‐44‐8
C Product: CARBIMAZOLE IMPURITIES
C Carbimazole EP Impurity A (Thiamazole/ Methimazole) 60‐56‐0
C Product: CARBINOXAMINE IMPURITIES
C Carbinoxamine Related Compound A 6318‐51‐0
C Product: CARBOPLATIN IMPURITIES
C Carboplatin EP Impurity A (Cisplatin) 15663‐27‐1
C 1,1‐Cyclobutanedicarboxylic Acid 5445‐51‐2
C Product: CARBOPROST IMPURITIES
C Trans‐Carboprost 76498‐29‐8
C 15‐epi Carboprost 148146‐51‐4
C Product: CARMUSTINE IMPURITIES
C Carmustine EP impurity A/ Carmustine Related Compound A (1,3‐Bis(2‐chloroethyl)urea) 2214‐72‐4
C Product: CARVEDILOL IMPURITIES
C Carvedilol EP Impurity A/ Carvedilol Related Compound A 1198090‐73‐1
C Carvedilol EP Impurity B/ Carvedilol Related Compound B 918903‐20‐5
C Carvedilol EP Impurity C/ Carvedilol Related Compound C 72955‐94‐3
C Carvedilol EP Impurity D/ Carvedilol Related Compound D (Carvedilol Epoxy Impurity) 51997‐51‐4
C Carvedilol EP Impurity E/ Carvedilol Related Compound E
1836‐62‐0
64464‐07‐9
C Carvedilol Impurity A 1076199‐79‐5
C Carvedilol (R)‐Isomer 95093‐99‐5
C Carvedilol (S)‐Isomer 95094‐00‐1
C Carvedilol Impurity (1,2,3,4‐Tetrahydro‐4‐oxocarbazole ) 206647‐27‐0
C Carvedilol Biscarbazole Impurity/ Carvedilol Diether Propanol Impurity 1276477‐91‐8
31.
C Carvedilol Amino Propanol 72955‐96‐5
C Carvedilol Propanediol Impurity 123119‐89‐1
C Carvedilol Amino ethanol impurity 10587‐65‐2
C Carvedilol Chloropropanol Impurity 1187921‐93‐2
C Carvedilol 4‐Hydroxycarbazole Impurity 52602‐39‐8
C Carvedilol N‐Isopropyl Impurity 1246819‐01‐1
C Carvedilol Dioxirane 1198090‐71‐9
C Carvedilol Bisalkylpyrocatechol Impurity/ Carvedilol O‐Desmethyl O‐Alkyl Impurity 1346602‐98‐9
C N2‐Methyl Carvedilol 72956‐35‐5
C N‐Methyl Carvedilol 933442‐47‐8
C Acetyl carvedilol 141353‐76‐6
C [3‐(9H‐Carbazol‐4‐yloxy)‐2‐hydroxy]propyl Carvedilol 1391052‐16‐6
C 1,2‐Phenylenedioxydiacetonitrile 27165‐64‐6
C 2‐(9H‐Carbazol‐4‐yloxy)ethanol
C 1‐(2‐chloroethoxy)‐2‐methoxy benzene 53815‐60‐4
C Cyclohexan‐1,3‐dion‐mono‐phenylhydrazon 27385‐45‐1
C N‐[2‐(2‐Methoxyphenoxy)ethyl]acetamide 293738‐17‐7
C 1,3‐Cyclohexanedione 504‐02‐9
C Tetrahydro keto carbazole 15128‐52‐6
C 9H‐Carbazole/ Dibenzopyrrole/ Diphenylenimine 86‐74‐8
C Product: CEFACLOR IMPURITIES
C Cefaclor EP Impurity A (Phenylglycine/ Cefalexin EP Impurity A ) 875‐74‐1
C Cefaclor EP Impurity B 53994‐69‐7
C Cefaclor EP Impurity C (Cefaclor (2S)‐Isomer)
C Cefaclor EP Impurity D (Cefaclor 3‐Ene Isomer) 152575‐13‐8
C Cefaclor EP Impurity F 2882‐18‐0
C Cefaclor EP Impurity H (N‐Phenylglycyl Cefaclor/ D‐Phenylglycyl Cefaclor)
C Product: CEFADROXIL IMPURITIES
C Cefadroxil EP Impurity A (Amoxicillin EP Impurity I/ Amoxicillin Related Compound I/ Cefoperazone Impurity 3) 22818‐40‐2
32.
C Cefadroxil EP Impurity H (Cefalexin EP Impurity E/ 7‐ADCA Pivalamide) 146794‐70‐9
C Product: CEFALEXIN IMPURITIES/ CEPHALEXIN IMPURITIES
C Cefalexin EP Impurity A (Cefaclor EP Impurity A/ Phenylglycine) 875‐74‐1
C Cefalexin EP Impurity B (7‐ADCA/ 7‐Aminodesacetoxycephalosporanic acid) 22252‐43‐3
C Cefalexin EP Impurity C (D‐Phenylglycyl Cephalexin) 72528‐40‐6
C Cefalexin EP Impurity D 34876‐35‐2
C Cefalexin EP Impurity F (Cefalexin 3‐Ene Isomer) 79750‐46‐2
C Product: CEFALOTIN IMPURITIES
C Cefalotin EP Impurity C (Cefoperazone EP Impurity E/ Cefazolin EP Impurity H/ 7‐Aminocephalosporanic Acid) 957‐68‐6
C Product: CEFAZOLIN IMPURITIES
C Cefazolin EP Impurity A 30246‐33‐4
C Cefazolin EP Impurity H (Cefoperazone EP Impurity E/ Cefalotin EP Impurity C/ 7‐Aminocephalosporanic Acid) 957‐68‐6
C Product: CEFEPIME IMPURITIES
C Cefepime EP Impurity E/ Cefepime Related Compound E 103121‐85‐3
C Cefepime EP Impurity G 120‐94‐5
C Product: CEFIXIME IMPURITIES
C Cefixime EP Impurity A 1614255‐90‐1
C Cefixime EP Impurity B 1335475‐19‐8
C Cefixime EP Impurity C (cefixime 7‐epimer) 108691‐83‐4
C Cefixime EP Impurity D (cefixime (E)‐isomer) 79350‐37‐1
C Cefixime EP Impurity E 72701‐01‐0
C Product: CEFOPERAZONE IMPURITIES
C Cefoperazone EP Impurity E (Cefalotin EP Impurity C/ Cefazolin EP Impurity H/ 7‐Aminocephalosporanic Acid) 957‐68‐6
C Cefoperazone Impurity 3 (Cefadroxil EP Impurity A/ Amoxicillin EP Impurity I/ Amoxicillin Related Compound I) 22818‐40‐2
C Product: CEFPROZIL IMPURITIES
C Cefprozil EP Impurity B 66592‐87‐8
C Product: CEFUROXIME IMPURITIES
C Cefuroxime 1‐Acetoxyethyl Ester 64544‐07‐6
C Product: CELECOXIB IMPURITIES
33.
C Celecoxib EP Impurity A/ Celecoxib Related Compound A (Celecoxib 3‐Methyl Analog) 170570‐01‐1
C Celecoxib EP Impurity B/ Celecoxib Related Compound B 331943‐04‐5
C Celecoxib Hydroxymethyl Analog 170571‐00‐3
C Celecoxib Related Compound 4 720‐94‐5
C Celecoxib Hydrazine Impurity 17852‐52‐7
C Celecoxib Impurity 2 948293‐46‐7
C Celecoxib Carboxylic Acid 170571‐01‐4
C Celecoxib 2‐Methyl Analog 170569‐99‐0
C Methyl 4‐methylbenzoate/ Methyl P‐toluate 99‐75‐2
C Celecoxib Impurity 7 (2,4 Dimethyl celecoxib) 170570‐09‐9
C Desmethyl Celecoxib 170569‐87‐6
C 3‐(Trifluoromethyl)‐5‐p‐tolyl‐1H‐pyrazole 26974‐15‐2
C 3‐Trifluoromethyl‐5‐(p‐tolyl)‐1H‐pyrazole 219986‐64‐8
C Product: CEPHALEXIN IMPURITIES
C Cefalexin EP Impurity E (Cefadroxil EP Impurity H/ 7‐ADCA Pivalamide) 146794‐70‐9
C N‐Ethoxycarbonyl‐7‐ADCA 72820‐16‐7
C Product: CETRIZINE IMPURITIES
C
Cetirizine EP Impurity A/ Cetirizine Related Compound A (Cetirizine CBHP Impurity/ Hydroxyzine EP Impurity A/
Hydroxyzine Related Compound A) 303‐26‐4
C Cetirizine EP Impurity B
113740‐61‐7
942132‐30‐1
942193‐17‐1
C Cetirizine EP Impurity C (Cetirizine 2‐Chloro Analog) 83881‐59‐8
C Cetirizine EP Impurity D/ Cetirizine Dimer Impurity (Hydroxyzine Impurity 2)
346451‐15‐8
856841‐95‐7
C Cetirizine EP Impurity E (Hydroxyzine Acetic Acid)
682323‐77‐9
83881‐56‐5
C Cetirizine EP Impurity F/ Deschloro Cetirizine Dihydrochloride
83881‐53‐2
83881‐54‐3
34.
C Cetirizine EP Impurity G/ Cetirizine Related Compound G (Cetirizine Ethanol Impurity)
109806‐71‐5
164726‐80‐1
728948‐88‐7
705289‐61‐8
C Cetirizine Impurity K (Deschloro Cetirizine tert‐Butyl Ester)
C Cetrizine Related Compound A/ Cetirizine Ethyl Ester 246870‐46‐2
C Cetirizine Methyl Ester
83881‐46‐3
83881‐48‐5
C Cetirizine 4‐Chlorobenzhydrol Impurity (Meclizine Related Compound A) 119‐56‐2
C Cetirizine 4‐Chlorobenzophenone Impurity 134‐85‐0
C Cetirizine N‐Oxide 1076199‐80‐8
C 3‐Chloro Cetirizine/ Cetirizine 3‐Chloro Impurity
1232460‐31‐9
1232460‐29‐5
C Cetirizine Glycerol Ester 1243652‐36‐9
C Cetirizine Polyethylene Glycol Ester 1509941‐93‐8
C Cetirizine R‐Isomer (LevoCetirizine)
130018‐77‐8
130018‐87‐0
C (R)‐Cetirizine N‐Oxide 442863‐80‐1
C Product: CHENODEOXYCHOLIC ACID IMPURITIES/ CDCA IMPURITIES
C Chenodeoxycholic Acid EP Impurity B (Ursodeoxycholic Acid EP Impurity B/ Cholic Acid) 81‐25‐4
C
Chenodeoxycholic Acid EP Impurity C (Ursodeoxycholic Acid EP Impurity C/ Lithocholic Acid/ 7‐Deoxy Ursodeoxycholic
Acid/ 7‐Deoxy Chenodeoxycholic Acid) 434‐13‐9
C Chenodeoxycholic Acid EP Impurity E (Ursodeoxycholic Acid EP Impurity E/ Deoxycholic Acid) 83‐44‐3
C
Chenodeoxycholic Acid EP Impurity F (Ursodeoxycholic Acid EP Impurity F/ 7‐Oxo Ursodeoxycholic Acid/ 7‐Oxo
Chenodeoxycholic Acid) 4651‐67‐6
C Chenodeoxycholic Acid EP Impurity G (Ursodeoxycholic Acid EP Impurity G/ Ursodeoxycholic Acid Methyl Ester) 10538‐55‐3
C 3,7‐Dioxo‐5beta‐cholanoic acid 859‐97‐2
35.
C Product: CHLORAMBUCIL IMPURITIES
C Propylparaben 94‐13‐3
C Product: CHLORDIAZEPOXIDE IMPURITIES
C Chlordiazepoxide EP impurity A/ Chlordiazepoxide Related Compund A (Demoxepam) 963‐39‐3
C Chlordiazepoxide EP impurity B 5958‐24‐7
C Chlordiazepoxide impurity C 719‐59‐5
C Product: CHLOROQUINE IMPURITIES
C Chloroquine Related Compound A (Amodiaquine Dichloro Impurity/ Hydroxychloroquine EP Impurity G) 86‐98‐6
C Desethyl Chloroquine (Hydroxychloroquine EP Impurity D) 1476‐52‐4
C Quininone 84‐31‐1
C Product: CHLORPHENIRAMINE IMPURITIES
C Chlorpheniramine EP Impurity A 1246816‐57‐8
C Chlorpheniramine EP Impurity B/ Chlorphenamine Related Compound B 1202‐34‐2
C Chlorpheniramine EP Impurity C 20619‐12‐9
C Chlorpheniramine EP Impurity D (Chlorpheniramine Nitrile Impurity) 65676‐21‐3
C 5‐Hydroxyindole‐3‐acetic acid 54‐16‐0
C Product: CHLORPROMAZINE IMPURITIES
C Chlorpromazine EP Impurity A 969‐99‐3
C Chlorpromazine EP Impurity B 19077‐20‐4
C Chlorpromazine EP Impurity C 58‐40‐2
C Chlorpromazine EP Impurity D 1225‐64‐5
C Chlorpromazine EP Impurity E 92‐39‐7
C Chlorpromazine N‐Oxide
1672‐76‐0
18683‐80‐2
C Product: CHLORTHALIDONE IMPURITIES
C Chlorthalidone EP Impurity B/ Chlorthalidone Related Compound A (Chlorthalidone Acid) 5270‐74‐6
C Chlorthalidone EP Impurity C (Chlorthalidone Acid Ethyl Ester) 92874‐73‐2
C Chlorthalidone EP Impurity D (Chlorthalidone Ethyl Ether/ O‐Ethyl Chlorthalidone)
1369995‐36‐7
1369588‐00‐0
36.
C Chlorthalidone EP Impurity E (Chlorthalidone Deshydroxy Impurity) 82875‐49‐8
C Chlorthalidone EP Impurity G (Chlorthalidone Dichloro Impurity) 16289‐13‐7
C Chlorthalidone Desulfonamide Impurity 956‐92‐3
C O‐Methyl Chlorthalidone/ Chlorthalidone Methyl Ether 6512‐76‐4
C Product: CHLORZOXAZONE IMPURITIES
C Chlorzoxazone Related Compound A 95‐85‐2
C Product: CHOLIC ACID IMPURITIES
C Glycochenodeoxycholic acid Sodium salt 16664‐43‐5
C Taurodeoxycholic acid Sodium salt 207737‐97‐1
C Product: CILASTATIN IMPURITIES
C Cilastatin EP Impurity A
C Cilastatin EP Impurity D (mesityl oxide) 141‐79‐7
C Cilastatin EP Impurity E 1174657‐07‐8
C Cilastatin EP Impurity F
C Cilastatin EP Impurity H
C L‐Cysteine hydrochloride monohydrate 7048‐04‐6
C N‐Acetyl‐L‐cysteine 616‐91‐1
C (S)‐(+)‐2,2‐Dimethylcyclopropanecarboxamide 75885‐58‐4
C 7‐Chloro‐2‐[[[(1S)‐2,2‐dimethylcyclopropyl]carbonyl]amino]‐2‐heptenoic acid 877674‐77‐6
C Product: CILNIDIPINE IMPURITIES
C Cilnidipine Impurity 1 (Nimodipine EP Impurity C/ Nimodipine Related Compound B) 70172‐96‐2
C Product: CILOSTAZOL IMPURITIES
C Cilostazol Related Compound A 54197-66-9
C Cilostazol Related Compound B 73963-62-9
C Cilostazol Related Compound C 865792-18-3
C Product: CIMETIDINE IMPURITIES
C Cimetidine EP Impurity D (Cimetidine Descyano Impurity) 59660‐24‐1
C Cimetidine EP Impurity G (2‐Cyano‐1,3‐dimethylguanidine) 31857‐31‐5
C Product: CINACALCET IMPURITIES
37.
C Cinacalcet Impurity A (Cinacalcet Amine Impurity) 3886‐70‐2
C Cinacalcet Impurity B 66469‐40‐7
C Cinacalcet Impurity C (Dehydro Cinacalcet) 955373‐56‐5
C Cinacalcet Impurity E 253337‐60‐9
C Cinacalcet Related Compund B (Cinacalcet Impurity D) 1271930‐15‐4
C Cinacalcet Related Compund D (Cinacalcet (S)‐Isomer/ ent‐Cinacalcet)
1217809‐88‐5
694495‐47‐1
C Cinacalcet N‐Oxide 1229224‐94‐5
C Cinacalcet Impurity 28 1201‐74‐7
C Cinacalcet Impurity 27 10420‐89‐0
C Cinacalcet Impurity 5 (Benzenebutanoic acid) 22156‐45‐2
C Cinacalcet Impurity 6 (4‐Phenylbutyric Acid) 1821‐12‐1
C Cinacalcet Impurity 39 (Imine N‐Oxide)
C 3‐(3‐Trifluoromethylphenyl)propionic acid 585‐50‐2
C 3‐(Trifluoromethyl)cinnamic acid 779‐89‐5
C Cinacalcet Amide Impurity 955371‐05‐8
C Cinacalcet Diastereo isomer‐1 2059891‐97‐1
C Cinacalcet Diastereo isomer‐2 2059891‐96‐0
C Cinacalcet Regio Isomer 2074615‐22‐6
C (αR)‐α‐Methyl‐N‐[[3‐(trifluoromethyl)phenyl]methyl]‐1‐naphthalenemethanamine Hydrochloride 1229512‐52‐0
C Product: CINNARIZINE IMPURITIES
C Cinnarizine EP Impurity A 841‐77‐0
C Cinnarizine EP Impurity B (cis‐Cinnarizine/ (Z)‐Cinnarizine) 750512‐44‐8
C Cinnarizine EP Impurity C 95062‐18‐3
C Cinnarizine EP Impurity D 1199751‐98‐8
C Cinnarizine EP Impurity E 216581‐01‐0
C Product: CIPROFLOXACIN IMPURITIES
C Ciprofloxacin Impurity‐A (EP)/ Enrofloxacin Impurity‐A (EP) (Fluoroquinolonic Acid) 86393‐33‐1
C Ciprofloxacin Impurity‐B (EP) (Desfluoro Ciprofloxacin) 93107‐11‐0
38.
C Ciprofloxacin Impurity‐C (EP)/ Enrofloxacin Impurity‐G (EP) (Ciprofloxacin ethylenediamine compound)‐FREE BASE 103222‐12‐4
C Ciprofloxacin Impurity‐C (EP)/ Enrofloxacin Impurity‐G (EP) (Ciprofloxacin ethylenediamine compound)‐HCL SALT 528851‐31‐2
C Ciprofloxacin Impurity‐D (EP) (7‐Chloro‐6‐piperazin‐1‐yl) 133210‐96‐5
C Ciprofloxacin Impurity‐E (EP) (Decarboxy Ciprofloxacin) 105394‐83‐0
C Ciprofloxacin EP Impurity F 226903‐07‐7
C 6‐Chloro‐6‐defluoro Ciprofloxacin/ Ciprofloxacin 6‐Chloro Analog 93106‐58‐2
C Ciprofloxacin 7‐Chloro‐6‐Desethylene Impurity 528851‐30‐1
C Ciprofloxacin N‐Formyl Impurity 93594‐39‐9
C
Ciprofloxacin Difluoro 8‐Methoxy Impurity (Gatifloxacin Related Compound C/ Moxifloxacin Difluoro Methoxy Acid
Impurity) 112811‐72‐0
C N‐Ethoxycarbonyl‐ciprofloxacin 93594‐29‐7
C Product: CISPLATIN IMPURITIES
C Cisplatin EP Impurity A (Transplatin) 14913‐33‐8
C Cisplatin EP Impurity B (Potassium Trichloroammineplatinate) 13820‐91‐2
C Product: CITALOPRAM IMPURITIES
C Citalopram EP Impurity A/ Citalopram Related Compound A (EsCitalopram EP Impurity A/ Citalopram Amide) 64372‐56‐1
C Citalopram EP Impurity B/ Citalopram Related Compund B (3‐Hydroxy Citalopram) 411221‐53‐9
C Citalopram EP Impurity C/ Citalopram Related Compund C (3‐Oxo Citalopram) 372941‐54‐3
C Citalopram EP Impurity D/ Citalopram Related Compound D (EsCitalopram EP Impurity D/ N‐Desmethyl Citalopram)
62498‐67‐3
97743‐99‐2
1188264‐72‐3
C Citalopram EP Impurity E/ Citalopram Related Compound G (Citalopram 5‐Chloro Analog) 64169‐46‐6
C Citalopram EP Impurity F/ Citalopram Related Compound H (5‐Bromo Citalopram)
64169‐39‐7
479065‐02‐6
C Citalopram EP Impurity G/ Citalopram ketone (Citalopram Dimethylaminobutanone/ Escitalopram EP Impurity G) 1329745‐98‐3
C Citalopram Related Compound E (Escitalopram EP Impurity H/ Citalopram N‐Oxide) 63284‐72‐0
39.
C Citalopram Related Compound F
29869‐90‐7
55011‐89‐7
C Citalopram EP Impurity I (Citalopram Olefinic Impurity) 920282‐75‐3
C Citalopram N‐Desmethyl S‐Isomer 144025‐14‐9
C Citalopram Carboxylic Acid Impurity/ Descyano Citalopram Carboxylic Acid (EsCitalopram EP Impurity M) 440121‐09‐5
C Citalopram S‐Isomer (Escitalopram) 219861‐08‐2
C Citalopram R‐Isomer (EsCitalopram EP Impurity K)
219861‐53‐7
128196‐02‐1
C (S)‐Citalopram N‐Oxide 917482‐45‐2
C Citalopram Benzofuran analog 64169‐67‐1
C DPTTA Salt 32634‐66‐5
C (S)‐Citalopram Fluorophenylmethanone Impurity (Escitalopram Impurity E)
1217846‐84‐8
1217846‐85‐9
C Citalopram Dihydroxy Impurity (Escitalopram EP Impurity E/ Escitalopram Related Compound A/ Citadiol)
103146‐25‐4
103146‐26‐5
128173‐53‐5
C Desfluoro Citalopram
1026009‐77‐7
1093072‐86‐6
C Citalopram Desfluoro Impurity (EsCitalopram EP Impurity L) 1346617‐30‐8
C 5‐aminoisobenzofuran‐1(3H)‐one 65399‐05‐5
C Didesmethyl Citalopram 166037‐78‐1
C 4‐(4‐(dimethylamino)‐1‐(4‐fluorophenyl)‐1‐hydroxybutyl)‐3‐(hydroxymethyl)benzonitrile hydrochloride 717133‐25‐0
C Product: CITICOLINE IMPURITIES
C Uridine 5‐diphosphate choline 99492‐83‐8
C Product: CLARITHROMYCIN IMPURITIES
C Clarithromycin EP Impurity C (Clarithromycin 9‐Oxime/ 6‐O‐Methylerythromycin A (E)‐9‐oxime)
103450‐87‐9
127253‐06‐9
C Clarithromycin EP Impurity D (N‐Desmethyl Clarithromycin/ N‐Demethyl‐6‐O‐methylerythromycin A) 101666‐68‐6
40.
C Clarithromycin EP Impurity E/ Clarithromycin Related Compound A (6,11‐Di‐O‐methylerythromycin A) 81103‐14‐2
C Clarithromycin EP Impurity G (Clarithromycin (9E)‐O‐Methyloxime/ 6‐O‐Methylerythromycin A (E)‐9‐(O‐methyloxime)) 127182‐44‐9
C Clarithromycin EP Impurity H (N‐Demethyl‐N‐formyl Clarithromycin) 127140‐69‐6
C Clarithromycin EP Impurity I (Des(cladinosyl) Clarithromycin/ 3‐O‐Decladinosyl‐6‐O‐methylerythromycin A) 118058‐74‐5
C
Clarithromycin EP Impurity J (Roxithromycin Impurity C/ Erythromycin Oxime/ Azithromycin Impurity S/ 9‐
Erythromycin A Oxime) 13127‐18‐9
C Clarithromycin EP Impurity K 127157‐35‐1
C Clarithromycin EP Impurity L (Clarithromycin A (Z)‐9‐oxime/ 6‐O‐Methylerythromycin A (Z)‐9‐oxime) 127253‐05‐8
C Clarithromycin EP Impurity M 127182‐43‐8
C Clarithromycin EP Impurity N (10,11‐Anhydro Clarithromycin) 144604‐03‐5
C Clarithromycin EP Impurity O (Clarithromycin (9Z)‐O‐Methyloxime/ 6‐O‐Methylerythromycin A (Z)‐9‐(O‐methyloxime)) 127252‐80‐6
C Clarithromycin EP Impurity Q (Clarithromycin N‐Oxide/ 6‐O‐Methyl Erythromycin N‐Oxide) 118074‐07‐0
C
Clarithromycin EP Impurity R (N‐Desmethyl 6‐O‐Desmethyl Clarithromycin/ N‐Desmethyl Erythromycin A/ Erythromycin
EP Impurity B/ Erythromycin Related Compund N) 992‐62‐1
C 14‐hydroxy Clarithromycin 116836‐41‐0
C Product: CLINDAMYCIN IMPURITIES
C Clindamycin sulphone 887402‐22‐4
C Clindamycin Sulfoxide (7(S)‐Chloro‐7‐Deoxy‐Lincomycin Sulfoxide) 22431‐46‐5
C Product: CLIOQUINOL IMPURITIES
C Clioquinol EP Impurity C 83‐73‐8
C Product: CLOBAZAM IMPURITIES
C Clobazam EP Impurity A (N‐Desmethylclobazam) 22316‐55‐8
C Clobazam EP Impurity B 22316‐24‐1
C Clobazam EP Impurity C 22316‐16‐1
41.
C Clobazam EP Impurity D NA
C Clobazam EP impurity E 75524‐13‐9
C 1‐(4‐Aminobenzyl)1,2,4triazole 119192‐10‐8
C Product: CLOBETASOL IMPURITIES
C Clobetasol Propionate Impurity‐A (EP)/ Betamethasone Dipropionate Impurity B (EP) (Betamethasone 17‐Propionate) 5534‐13‐4
C Clobetasol Propionate EP Impurity B 1356190‐17‐4
C Clobetasol Propionate Impurity‐C (EP) 25122‐52‐5
C Clobetasol Propionate Impurity‐G (EP)/ Betamethasone Impurity B (EP) 25122‐41‐2
C Clobetasol Propionate Impurity‐I (EP) (Betamethasone 17‐Propionate 21‐Mesylate) 15423‐80‐0
C Clobetasol Propionate EP Impurity J/ Clobetasol Propionate Related Compound A 1486466‐31‐2
C Clobetasol Propionate Impurity‐K (EP)/ Betamethasone Dipropionate Impurity C (EP) (Betamethasone 21‐Propionate) 75883‐07‐7
C Product: CLOFARABINE IMPURITIES
C Clofarabine Alpha Anomer Impurity 491594‐60‐6
C Product: CLOFAZIMINE IMPURITIES
C Clofazimine OXO Impurity 90712‐89‐3
C Product: CLOMIPRAMINE IMPURITIES
C Clomipramine EP Impurity A
C Clomipramine EP Impurity B (Imipramine HCl/ Trimipramine EP Impurity D) 113‐52‐0
C Clomipramine Hydrochloride EP Impurity C 2095‐42‐3
C Clomipramine EP Impurity D
115189‐28‐1
3589‐22‐8
C Clomipramine EP Impurity E (Iminobibenzyl/ Carbamazepine EP Impurity E/ Trimipramine EP Impurity F) 494‐19‐9
C Clomipramine EP Impurity F (Carbamazepine 3‐Chloroiminodibenzyl Impurity) 32943‐25‐2
C Clomipramine EP Impurity G 1425793‐87‐8
C Clomipramine N‐Oxide 14171‐67‐6
C N‐Desmethyl Clomipramine 29854‐14‐6
C N‐(2,6‐Dichlorophenyl)‐carbonimidic Dichloride 21709‐18‐2
C Product: CLOPIDOGREL IMPURITIES
42.
C Clopidogrel EP Impurity A/ Clopidogrel USP Related Compound A (Clopidogrel Acid S‐Isomer)
144457‐28‐3
144750‐42‐5
C Clopidogrel EP Impurity C/ Clopidogrel USP Related Compound C (Clopidogrel R‐Isomer)
120202‐69‐9
120202‐71‐3
C Clopidogrel EP Impurity D 1421283‐60‐4
C Clopidogrel Impurity E
C Clopidogrel USP Related Compound B
144750‐52‐7
1396607‐35‐4
C Clopidogrel Pyridinium Impurity
1251736‐87‐4
1396607‐49‐0
C 2‐Chloromandelic Acid 10421‐85‐9
C Clopidogrel Hydroxy Impurity (2‐Chloromandelic Acid Methyl Ester) 32345‐60‐1
C Clopidogrel Acid R‐Isomer 324757‐50‐8
C Clopidogrel Amide Impurity (Ticlodipine EP Impurity B/ Ticlodipine Related Compound A) 68559‐60‐4
C Clopidogrel Glutathione Disulfide 1118605‐95‐0
C Product: CLOTRIMAZOLE IMPURITIES
C Clotrimazole EP Impurity A/ Clotrimazole USP Related Compound A 66774‐02‐5
C Clotrimazole EP Impurity B (Clotrimazole p‐Chloro Isomer) 23593‐71‐7
C Clotrimazole EP Impurity C (2‐Chlorotrityl Chloride) 42074‐68‐0
C Clotrimazole EP Impurity D (Enalapril EP Impurity I/ Ondansetron EP Impurity E/ Imidazole/ Bifonazole EP Impurity C) 288‐32‐4
C Clotrimazole EP Impurity E 5162‐03‐8
C Clotrimazole EP Impurity F (Deschloro Clotrimazole) 15469‐97‐3
C 3‐Chlorobenzotrichloride 2136‐81‐4
C Product: CLOXACILLIN IMPURITIES
C
Cloxacillin EP Impurity C (Ampicillin EP Impurity A/ Amoxicillin EP Impurity A/ Amoxicillin Related Compound A/
Flucloxacillin EP Impurity C/ Piperacillin EP Impurity H/ Sulbactam EP Impurity B/ 6‐Aminopenicillanic Acid) 551‐16‐6
C Product: CLOZAPINE IMPURITIES
C Clozapine EP Impurity A 50892‐62‐1
43.
C Clozapine EP Impurity B 263366‐81‐0
C Clozapine EP Impurity C (N‐Desmethyl Clozapine) 6104‐71‐8
C Clozapine EP Impurity D 65514‐71‐8
C Clozapine N‐oxide 34233‐69‐7
C Product: COLCHICINE IMPURITIES
C Colchicine EP Impurity E (3‐O‐Demethyl Colchicine) 7336‐33‐6
C Product: COLESEVELAM IMPURITIES
C Colesevelam Aminoquat Impurity 33968‐67‐1
C Colesevelam Decyl Aminoquat Impurity 359436‐99‐0
C Coesevelam 6‐bromo Impurity 32765‐81‐4
C Colesevelam Hydroxyquat Impurity 118843‐18‐8
C Colesevelam Methoxyquat Impurity 359436‐97‐8
C 1‐Decylamine 2016‐57‐1
C Trimethylamine 593‐81‐7
C Product: CROSPOVIDONE IMPURITIES
C Crospovidone EP Impurity A 88‐12‐0
C Product: CYCLIZINE IMPURITIES
C Cyclizine impurity A/ Cyclizine Related Compound A (Imatinib EP Impurity G/ 1‐Methylpiperazine)
109‐01‐3
34352‐59‐5
C Cyclizine impurity B 91‐01‐0
C Product: CYCLOBENZAPRINE IMPURITIES
C Cyclobenzaprine N‐Oxide 6682‐26‐4
C Cyclobenzaprine Related Compound B (Desmethyl Cyclobenzaprine/ Nortriptyline EP Impurity B)
303‐50‐4
438‐59‐5
C Product: CYCLOPENTOLATE IMPURITIES
C Cyclopentolate EP Impurity B (Tropicamide EP Impurity D/ Tropicamide Related Compound D/ Phenylacetic acid) 103‐82‐2
C Product: CYCLOPHOSPHAMIDE IMPURITIES
C Cyclophosphamide Related Compound A 821‐48‐7
C Cyclophosphamide Related Compound C 1071‐28‐9
C Product: CYCLOSERINE IMPURITIES
44.
C Cycloserine Impurity 1 (D‐Serine) 312‐84‐5
C Cycloserine Impurity 2 (D‐Serine methyl ester hydochloride) 5874‐57‐7
C Cycloserine Impurity 3 (3‐Chloro‐D‐alanine methyl ester hydochloride) 112346‐82‐4
C Cycloserine Impurity 4 (L‐Cycloserine) 339‐72‐0
C Cycloserine Impurity (L‐Serine) 56‐45‐1
C Cycloserine Impurity (L‐Serine methyl ester hydochloride) 5680‐80‐8
C Cycloserine Impurity (3‐Chloro‐L‐alanine methyl ester hydochloride) 17136‐54‐8
C D‐Cycloserine dimer 16337‐02‐3
C Cycloserine Diketopiperazine 1204‐99‐5
C Product: CYHALOFOP IMPURITIES
C Butyl‐2‐(4‐sec‐butoxyphenoxy)propanoate
C Product: CYPROHEPTADINE IMPURITIES
C
Cyproheptadine EP Impurity B (Amitriptyline EP Impurity A/ Amitriptyline Related Compound A (Nortriptyline EP
Impurity A/ Dibenzosuberone) 1210‐35‐1
C Product: CYTARABINE IMPURITIES
C Cytarabine EP Impurity B (Uridine) 58‐96‐8
D Product: DABIGATRAN IMPURITIES
D Dabigatran Impurity C (O‐(2‐Ethylbutyl) Dabigatran Ethyl Ester) 1610758‐20‐7
D Dabigatran Impurity D (O‐Butyl Dabigatran Ethyl Ester) 1416446‐43‐9
D Dabigatran Impurity E (O‐(2‐Heptyl) Dabigatran Ethyl Ester) 1610758‐21‐8
D Dabigatran Impurity F/ Impurity 9 211915‐00‐3
D Dabigatran Impurity F/ Impurity 9 (SALT FORM) 847785‐94‐8
D Dabigatran Impurity G (O‐(3‐Hexyl) Dabigatran Ethyl Ester) 1610758‐22‐9
D O‐Desethyl O‐Isopropyl Dabigatran Etexilate 1610758‐19‐4
D Dabigatran Impurity 3
D Dabigatran Impurity 10 1304574‐20‐6
D O‐Desethyl Dabigatran Etexilate 212321‐78‐3
D Dabigatran N‐Pyridylamide 1637238‐96‐0
D Dabigatran Impurity 6
D Desiminomethyl Carbonyl Dabigatran Etexilate 1408238‐40‐3
45.
D Dabigatran Etexilate Mesylate Impurity A 1408238‐37‐8
D Dabigatran Etexilate Despyridyl Ethyl Ester 1408238‐36‐7
D O‐Desethyl Dabigatran Etexilate 212321‐78‐3
D Dabigatran Ethyl Ester Cyano Analog 211915‐84‐3
D
2‐[[[4‐(Aminoiminomethyl)phenyl]amino]methyl]‐1‐methyl‐1H‐benzimidazole‐5‐carboxylic Acid Ethyl Ester
Hydrochloride 1422435‐39‐9
D Dabigatran Etexilate N‐Oxide 1381757‐44‐3
D Dabigatran Isopropyl Ester Impurity 1610758‐17‐2
D Dabigatran Methyl Ester 771459‐37‐1
D O‐Octyl Dabigatran Ethyl Ester 211915‐07‐0
D Dabigatran Acid Cyano Analog 212322‐77‐5
D Ethyl 3‐(Pyridin‐2‐ylamino)propanoate 103041‐38‐9
D Desethyl Dabigatran Etexilate Carboxamide 1580491‐16‐2
D Dabigatran Ethyl Ester 429658‐95‐7
D Ethyl 3‐Amino‐4‐(methylamino)benzoate 66315‐23‐9
D Dabigatran Acid 211914‐51‐1
D N‐Methoxycarbonyl Dabigatran Ethyl Ester 211914‐96‐4
D N‐Ethoxycarbonyl Dabigatran Ethyl Ester 1416446‐40‐6
D Dabigatran Methylamino Impurity 212322‐56‐0
D Product: DACARBAZINE IMPURITIES
D Dacarbazine EP Impurity B/ Dacarbazine Related Compound A 72‐40‐2
D Dacarbazine EP Impurity D (Imatinib EP Impurity I/ Metformin EP Impurity F) 506‐59‐2
D Hypoxanthine 2‐Aza Impuirty (Dacarbazine Related Compound B/ Temozolomide EP Impurity E)
4656‐86‐4
1797817‐35‐6
D Product: DACLATASVIR IMPURITIES
D 4,4'‐Diacetylbiphenyl 787‐69‐9
D 4,4‐Bis‐2‐bromoacetylbiphenyl 4072‐67‐7
D 1H‐Benzotriazole 95‐14‐7
D N‐(Methoxycarbonyl)‐L‐valine 74761‐42‐5
D N‐Boc‐L‐proline 15761‐39‐4
46.
D 1H‐IMidazole, 5,5'‐[1,1'‐biphenyl]‐4,4'‐diylbis[2‐(2S)‐2‐pyrrolidinyl‐, hydrochloride 1009119‐83‐8
D Di‐tert‐butyl2,2'‐([1,1'‐biphenyl]‐4,4'‐diylbis(1H‐imidazole‐5,2‐diyl))(2S,2'S)‐bis(pyridineidine‐1‐carboxylate) 1007882‐23‐6
D 1,2‐Pyrrolidinedicarboxy lic acid,2,2'‐[[1,1'‐biphenyl]‐4,4'‐diylbis(2‐oxo‐2,1‐ethanediyl)] bis[1‐(1,1‐dimethylethyl)] ester 1009119‐82‐7
D Product: DALFAMPRIDINE IMPURITIES
D Dalfampridine methylene Bridge Impurity
D Product: DANTROLENE IMPURITIES
D Dantrolene Related Compound A 301359‐05‐7
D Product: DAPAGLIFLOZIN IMPURITIES
D Dapagliflozin Impurity B 1662702‐90‐0
D Dapagliflozin Despyranose Bromo Impurity 461432‐23‐5
D (4‐chloro‐3‐(4‐ethoxybenzyl)phenyl)trimethylsilane
D Acetyl Dapagliflozin 461432‐25‐2
D Dapagliflozin Hydroxy Impurity 960404‐86‐8
D 5‐bromo 2‐chlorophenyl‐4‐ethoxyphenyl methanol 1280647‐32‐6
D Ethoxy benzene 103‐73‐1
D (5‐bromo‐2‐chlorophyl)(4‐ethoxyphenyl)methanone 461432‐22‐4
D 4,4’‐Dichloro‐3‐(3‐ethoxybenzyl)‐3’‐(4‐ethoxybenzyl)‐1,1’‐biphenyl 2176485‐21‐3
D Dapagliflozin O‐Desethyl Impurity 864070‐37‐1
D 2,3,4,6‐Tetrakis‐O‐trimethylsilyl‐D‐gluconolactone 32384‐65‐9
D 5‐Bromo‐2‐chlorobenzoic Acid 21739‐92‐4
D Product: DAPOXETINE IMPURITIES
D Dapoxetine N‐oxide 1346603‐24‐4
D N‐Desmethyl Dapoxetine 157166‐71‐7
D Product: DAPSONE IMPURITIES
D Dapsone N‐Acetyl Impurity/ Monoacetyl Dapsone 565‐20‐8
D N,N'‐Diacetyl Dapsone/ Acedapsone 77‐46‐3
D Product: DARIFENACIN IMPURITIES
D Darifenacin Morpholine Amide Impurity (Ethanethione) 97483‐11‐9
47.
D Darifenacin Carboxylic Acid Impurity 1048979‐16‐3
D 3‐Hydroxy Darifenacin 1285875‐62‐8
D Darifenacin 5‐Bromoethyl Impurity 127264‐14‐6
D Darifenacin Cyano Pyrrolidine Impurity
133099‐11‐3
194602‐27‐2
D Darifenacin Pyrrolidine (S)‐Isomer
134002‐25‐8
134002‐26‐9
D Darifenacin 4‐Hydroxy Impurity
D Darifenacin Pyrrolidinium Dimer Impurity 1396968‐57‐2
D Darifenacin Nitrile Impurity 252317‐48‐9
D Darifenacin N‐Oxide Impurity 1391080‐40‐2
D Diphenylacetonitrile 86‐29‐3
D (3S)‐1‐[(4‐Methylphenyl)sulfonyl]‐3‐pyrrolidinol 943587‐25‐5
D 1(S)‐1‐tosylpyrrolidin‐3‐yl 4‐methylbenzenesulfonate 133034‐01‐2
D (S)‐2,2‐diphenyl‐2‐(1‐tosylpyrrolidin‐3‐yl)acetonitrile 133099‐09‐9
D
N‐((3‐(2‐amino‐2‐oxo‐1,1‐diphenylethyl)pyrrolidin‐1‐yl)methyl)‐2‐((S)‐1‐(2‐(2,3‐dihydrobenzofuran‐5‐
yl)ethyl)pyrrolidin‐3‐yl)‐2,2‐diphenylacetamide
D Product: DASATINIB IMPURITIES
D Dasatinib N4‐Oxide 910297‐52‐8
D N‐Deshydroxyethyl Dasatinib 910297‐51‐7
D Dasatinib Dimer Impurity 910297‐61‐9
D Dasatinib Deschloro Impurity 1184919‐23‐0
D 4,6‐Dichloro‐2‐methylpyrimidine 1780‐26‐3
D 2‐amino‐N‐(2‐chloro‐6‐methylphenyl)thiazole‐5‐carboxamide 302964‐24‐5
D Dasatinib Dichloro Impurity 302964‐08‐5
D 2’‐Deschloro‐2’‐hydroxy Dasatinib 1159977‐25‐9
D Hydroxymethyl Dasatinib 910297‐58‐4
D Dasatinib Dimer Impurity 910297‐61‐9
D 2‐(tert‐Butoxycarbonylamino)thiazole‐5‐carboxylic Acid 302964‐02‐9
D 2‐(6‐chloro‐2‐methylpyrimidin‐4‐ylamino)thiazole‐5‐carboxylic acid 1251716‐89‐8
48.
D 2‐[[6‐[4‐(2‐Hydroxyethyl)‐1‐piperazinyl]‐2‐methyl‐4‐pyrimidinyl]amino]‐5‐thiazolecarboxylic acid 1245157‐42‐9
D Ethyl 2‐Aminothiazole‐5‐carboxylate 32955‐21‐8
D 1‐(2‐Hydroxyethyl)piperazine 103‐76‐4
D Product: DECITABINE IMPURITIES
D Decitabine impurity (ring‐opening)
D Decitabine Triazinone Impurity (Azacitidine Related Compound A/ 5‐Aza Cytosine) 931‐86‐2
D Methyl 2‐Deoxy‐D‐erythro‐pentopyranoside Bis(4‐methylbenzoate) 78103‐18‐1
D Methyl 2‐deoxy‐D‐erythro‐pentopyranoside 863396‐35‐4
D Product: DEFERASIROX IMPURITIES
D Deferasirox Methyl Ester 1266741‐05‐2
D Deferasirox Ethyl Ester 201530‐79‐2
D 4‐Hydrazinobenzoic acid 619‐67‐0
D Deferasirox Benzoxazin Impurity 1218‐69‐5
D Oxaphenamide 526‐18‐1
D Salicylamide 65‐45‐2
D Deferasirox Diacyl Impurity 1972‐71‐0
D Product: DEMBREXINE IMPURITIES
D Dembrexine EP Impurity D (Salicylaldehyde/ 2‐Hydroxybenzaldehyde) 90‐02‐8
D Product: DERACOXIB IMPURITIES
D 3’‐Fluoro‐4’methoxyacetophenone 455‐91‐4
D 4[N’‐[1‐[3‐Fluoro‐4‐methoxy‐phenyl)‐ethylidene]hydrazino}benzenesulfonamide 1798429‐38‐5
D Benzene sulphonamide 98‐10‐2
D Product: DESIPRAMINE IMPURITIES
D Imipramine HCl (Trimipramine EP Impurity D/Clomipramine EP Impurity B) 113‐52‐0
D Iminobibenzyl (Carbamazepine EP Impurity E/ Trimipramine EP Impurity F/ Clomipramine EP Impurity E) 494‐19‐9
D Desipramine Ethyl Carbamate 27097‐69‐4
D Dehydrodesipramine 2010‐13‐1
D Product: DESLORATIDINE IMPURITIES
D Desloratadine EP Impurity A 298220‐99‐2
49.
D Desloratadine EP Impurity B/ Desloratadine Related Compound B (Iso Desloratadine)
183198‐49‐4
432543‐89‐0
D Desloratadine EP Impurity C (Loratadine) 79794‐75‐5
D Desloratadine Related Compound A (Desloratadine 8‐Bromo Analog) 117796‐50‐6
D Desloratadine Related Compound F (Desloratadine N‐Formyl Impurity/ Loratadine N‐Formyl Impurity) 117810‐61‐4
D Desloratadine 8‐Bromo‐N‐Methyl Impurity 130642‐57‐8
D N‐Methyl Desloratadine (Loratidine EP Impurity G/ Loratidine Related Compound B/ 8‐Chloro Azatadine) 38092‐89‐6
D Desloratadine Deschloro Impurity (Loratadine impurity A/ N‐Desmethyl Azatadine) 38092‐95‐4
D Desloratadine N‐Hydroxy Impurity 1193725‐73‐3
D Desloratadine Pyridine N‐Oxide 169253‐26‐3
D Desloratadine 11‐Hydroxy N‐Methyl Impurity (Loratidine Related Compound D) 38089‐93‐9
D Desloratadine Methanone Impurity/ Desloratadine Ketone Impurity (Loratadine Methanone Impurity) 119770‐60‐4
D Desloratadine 3‐Hydroxy Impurity (Loratadine Desethoxycarbonyl 3‐Hydroxy Impurity) 119410‐08‐1
D Desloratadine Dehydro Impurity 117811‐20‐8
D Product: DESVENLAFAXINE IMPURITIES
D Desvenlafaxine N‐Dimer (Venlafaxine O‐Desmethyl N‐Dimer) 1187545‐61‐4
D Desvenlafaxine‐N‐oxide (O‐Desmethyl Venlafaxine N‐Oxide) 1021933‐95‐8
D Desvenlafaxine Spiro Impurity (Venlafaxine O‐Desmethyl Cyclic Impurity/ Desvenlafaxine Cyclic Impurity) 1346601‐55‐5
D Desvenlafaxine Anhydro Impurity (Venlafaxine O‐Desmethyl Anhydro Impurity) 1346600‐38‐1
D Product: DEXAMETHASONE IMPURITIES
D Dexamethasone EP Impurity D (Mometasone Furoate EP Impurity L) 24916‐90‐3
D Dexamethasone EP Impurity G (Betamethasone Acetate EP Impurity B/ 21‐O‐Acetyl Dexamethasone) 1177‐87‐3
D 21‐Dehydro Dexamethasone 17‐Propionate 62800‐58‐2
D Dexamethasone‐∆17,20 21‐Aldehyde 6762‐51‐2
D Product: DEXLANSOPRAZOLE IMPURITIES
D Lansoprazole S‐Isomer/ Levolansoprazole 138530‐95‐7
D Product: DEXTROMETHORPHAN IMPURITIES
50.
D Dextromethorphan Impurity A 1531‐25‐5
D Dextromethorphan Impurity B 1021868‐94‐9
D Dextromethorphan Impurity C (10‐Keto Dextromethorphan) 57969‐05‐8
D N‐Desmethyldextromethorphan 1087‐69‐0
D N‐Formyl Dextromethorphan 28973‐48‐0
D N,N‐Dimethylaniline 121‐69‐7
D Dextromethorphan N‐Oxide
1177419‐85‐0
210690‐24‐7
D Product: DIACEREIN IMPURITIES
D Diacerein EP Impurity H (Triacetyl Aloe Emodin) 25395‐11‐3
D Product: DIAZEPAM IMPURITIES
D Diazepam EP Impurity B 6021‐21‐2
D Diazepam EP Impurity C/ Diazepam Related Compound B 5220‐02‐0
D Diazepam EP Impurity E 20927‐53‐1
D Diazepam Impurity F 31269‐33‐7
D Desmethyldiazapam/ Nordazepam 1088‐11‐5
D Diazepam Related Compound A 1022‐13‐5
D Diazepam ‐ In house Impurity (Phenylboronic Acid) 98‐80‐6
D DIAZEPAM ‐ IN HOUSE IMPURITY 784‐41‐8
D 2'‐Benzoyl‐2,4'‐dichloroacetanilide 4016‐85‐7
D Product: DICLOFENAC IMPURITIES
D Diclofenac EP Impurity A/ Diclofenac Related Compound A (Diclofenac Amide/ Aceclofenac EP Impurity I) 15362‐40‐0
D Diclofenac EP Impurity B/ Diclofenac Related Compound B 22121‐58‐0
D Diclofenac EP Impurity C/ Diclofenac Related Compound C 27204‐57‐5
D Diclofenac EP Impurity D/ Diclofenac Related Compound D 127792‐45‐4
D Diclofenac EP Impurity E/ Diclofenac USP Related Compound E 59‐48‐3
D Diclofenac EP Impurity F/ Diclofenac Related Compound F 560075‐65‐2
D Diclofenac Ethyl Ester (Aceclofenac EP Impurity C) 15307‐77‐4
D Diclofenac isopropyl ester 66370‐79‐4
D Diclofenac Methyl Ester (Aceclofenac EP Impurity B) 15307‐78‐5
51.
D Diethyl Phthalate 84‐66‐2
D 2,6‐Dichloroaniline 608‐31‐1
D Diclofenac Desacetate Impurity 15307‐93‐4
D Diclofenac Chloroacetyl Impurity 15308‐01‐7
D N‐(2,6‐Dichlorophenyl)isatin 24542‐74‐3
D Diclofenac Carboxylic Acid 13625‐57‐5
D Diclofenac Glyoxillic Acid 66156‐75‐0
D Product: DICYCLOVERINE IMPURITIES
D Dicycloverine EP Impurity A 60263‐54‐9
D Product: DIDANOSINE IMPURITIES
D Didanosine EP Impurity A/ Didanosine Related Compound A (Azathioprine EP Impurity F/ Hypoxanthine) 68‐94‐0
D Product: DIHYDRALAZINE IMPURITIES
D Hydralazine
304‐20‐1
86‐54‐4
D Product: DIHYDROERGOTAMINE IMPURITIES
D 8’‐Hydroxy Dihydro Ergotamine 90650‐44‐5
D Product: DILTIAZEM IMPURITIES
D Diltiazem EP Impurity A 103532‐27‐0
D Diltiazem EP Impurity B 87447‐47‐0
D Diltiazem EP Impurity C (O‐Desmethyl Diltiazem) 142926‐07‐6
D Diltiazem EP Impurity D (N‐Desmethyl Diltiazem) 130606‐60‐9
D Diltiazem EP Impurity E 42399‐49‐5
D Diltiazem EP Impurity F (O‐Desacetyl Diltiazem)
42399‐40‐6
23515‐45‐9
D Diltiazem EP Impurity G/ Diltiazem Related Compound G (N‐Desmethyl O‐Desacetyl Diltiazem)
81353‐09‐5
86408‐44‐8
D Diltiazem EP Impurity H/ Diltiazem Related Compound H (N,N,O‐Tri‐Desmethyl Desacetyl Diltiazem) 115992‐91‐1
D Product: DIMENHYDRINATE IMPURITIES
D
Dimenhydrinate EP Impurity A (Diprophylline EP Impurity B/ Caffeine EP Impurity A/ Theophylline/ Pentoxifylline EP
Impurity C) 58‐55‐9
52.
D Dimenhydrinate EP Impurity E (8‐Chlorocaffeine) 4921‐49‐7
D Dimenhydrinate EP Impurity G (Diphenhydramine EP Impurity B)
19804‐27‐4
4024‐34‐4
D Product: DIMETHYL FUMARATE IMPURITIES
D Fumaric acid 110‐17‐8
D Malic acid 617‐48‐1
D Monomethyl Fumarate 2756‐87‐8
D Dimethyl maleate 624‐48‐6
D Monomethyl Maleate 3052‐50‐4
D Diltiazem N,N‐DiDesmethyl HCl 116050‐35‐2
D Diltiazem N‐Oxide 142843‐04‐7
D Diltiazem O‐Desacetyl‐O‐Desmethyl HCl 96252‐32‐3
D Diltiazem Sulfoxide 370094‐12‐5
D Diltiazem N‐Oxide O‐Desacetyl Impurity 122619‐90‐3
D Desacetyl N, O‐Didesmethyl Diltiazem 86408‐42‐6
D Product: DIPHENHYDRAMINE IMPURITIES
D Diphenhydramine EP Impurity A/ Diphenhydramine Related Compound A
17471‐10‐2
53499‐40‐4
D Diphenhydramine EP Impurity B (Dimenhydrinate EP Impurity G)
19804‐27‐4
4024‐34‐4
D Diphenhydramine EP Impurity C
118‐23‐0
1808‐12‐4
D Diphenhydramine EP Impurity D (Diphenylmethanol/ Benzhydrol) 91‐01‐0
D Diphenhydramine EP Impurity E (Diphenylmethanone/ Benzophenone/ Phenytoin EP Impurity A) 119‐61‐9
D Diphenhydramine N‐oxide 13168‐00‐8
D 3‐(Diphenylmethoxy)‐1,2‐propanediol, 3‐(Benzhydryloxy)propane‐1,2‐diol 19574‐66‐4
D Product: DIPROPHYLLINE IMPURITIES
D
Diprophylline EP Impurity B (Caffeine EP Impurity A/ Theophylline/ Dimenhydrinate EP Impurity A/ Pentoxifylline EP
Impurity C) 58‐55‐9
D Product: DIPYRIDAMOLE IMPURITIES
53.
D Dipyridamole EP Impurity A/ Dipyridamole Related Compound A 16982‐40‐4
D Dipyridamole EP Impurity B/ Dipyridamole Related Compound B 16908‐47‐7
D Dipyridamole EP Impurity C/ Dipyridamole Related Compound C 54093‐92‐4
D Dipyridamole EP Impurity D/ Dipyridamole Related Compound D 1176886‐12‐6
D Dipyridamole EP Impurity E/ Dipyridamole Related Compound E
D Dipyridamole EP Impurity F/ Dipyridamole Related Compound F 60286‐30‐8
D Dipyridamole EP Impurity G 7139‐02‐8
D 4‐Despiperidinyl‐4‐hydroxy Dipyridamole 68006‐07‐5
D Dipyridamole Tartaric Acid Ester Ammonium Salt 1246816‐97‐6
D Dipyridamole Tetrachloro Impurity 32980‐71‐5
D Dipyridamole Dichloro Dihydroxyethyl Impurity 1449029‐15‐5
D Dipyridamole Trichloro Impurity 1449029‐14‐4
D Product: DISOPYRAMIDE IMPURITIES
D Disopyramide EP Impurity A (Diisopyronitrile) 5005‐46‐9
D Disopyramide EP Impurity C
38236‐46‐3
1216619‐15‐6
D Product: DOBUTAMINE IMPURITIES
D Dobutamine EP Impurity A (Noradrenaline Impurity C/ Dopamine)
51‐61‐6
62‐31‐7
D Dobutamine EP Impurity B 5471‐51‐2
D Product: DOCETAXEL IMPURITIES
D Docetaxel EP Impurity B/ 6‐Oxo Docetaxel (10‐Deoxy‐10‐Oxo Docetaxel) 167074‐97‐7
D Docetaxel EP Impurity C/ 4‐Epi‐Docetaxel (7‐epi‐Docetaxel/7‐Epi‐Taxotere) 153381‐68‐1
D Docetaxel EP Impurity D/ 4‐Epi‐6‐Oxo Docetaxel (10‐Deoxy‐10‐Oxo‐7‐epi‐Docetaxel) 162784‐72‐7
D Docetaxel EP Impurity E (10‐Desacetyl Baccatin III) 32981‐86‐5
D 2’‐Epi Docetaxel 133577‐33‐0
D 7,10,13‐Tri‐O‐trichloroethoxycarbonyl‐10‐deacetyl Baccatin III 110258‐92‐9
D Product: DOFETILIDE IMPURITIES
D Dofetilide Related Compound A (Dofetilide N‐Desmethyl Impurity) 176447‐94‐2
54.
D N‐(4‐(2‐(methylamino)ethyl)phenyl)methane sulfonamide 115256‐16‐1
D Product: DOLUTEGRAVIR IMPURITIES
D Dolutegravir Impurity C (4‐Defluoro Dolutegravir) 1863916‐87‐3
D O‐Methyl Dolutegravir 1335210‐35‐9
D Dolutegravir 2‐Desfluoro Impurity 1863916‐88‐4
D Dolutegravir RR Isomer 1357289‐29‐2
D Dolutegravir SR Isomer 1309560‐49‐3
D Dolutegravir 2,6‐Difluoro Analog (Dolutegravir 4‐Desfluoro 6‐Fluoro Impurity) 2244161‐72‐4
D Dolutegravir Enantiomer Impurity 1309575‐43‐6
D Product: DOMPERIDONE IMPURITIES
D Domperidone EP Impurity A 53786‐28‐0
D Domperidone EP Impurity B 1346598‐11‐5
D Domperidone EP Impurity C (Domperidone N‐Oxide) 118435‐03‐3
D Domperidone EP Impurity D 1614255‐34‐3
D Domperidone EP Impurity E 1346602‐50‐3
D Domperidone EP Impurity F 1391053‐55‐6
D Product: DONEPEZIL IMPURITIES
D Donepezil Related Compound A (Donepezil Dehydro Impurity)
145546‐80‐1
120014‐07‐5
D Donepezil N‐Oxide 120013‐84‐5
D Donepezil Pyridine Dehydro N‐Oxide (Donepezil Alkene Pyridine N‐Oxide) 896134‐06‐8
D Donepezil Hydroxy Keto Impurity 197010‐20‐1
D Desbenzyl Donepezil Hydrochloride 120013‐39‐0
D Donepezil Desbenzyl Impurity ‐ Free base 120014‐30‐4
D Donepezil Pyridine Analog 4803‐57‐0
D Donepezil O‐Benzyl Enol Ether
D Desbenzyl Deoxy Impurity F ‐ Free Base 844694‐83‐3
D Desbenzyl Deoxy Impurity F 1034439‐43‐4
D Donepezil quaternary salt (Donepezil Benzyl Bromide/ Donepezilbenzyl) 844694‐85‐5
D Donepezil Dehydro Deoxy Impurity (Donepezil Indene Impurity) 120013‐45‐8
55.
D Donepezil Deoxy Impurity ‐ Free base 844694‐84‐4
D Donepezil Deoxy Impurity 1034439‐57‐0
D Donepezil 4‐Hydroxy Impurity 197010‐22‐3
D Donepezil Dihydro Impurity 120012‐04‐6
D Donepezil Indanone Impurity 2107‐69‐9
D Donepezil Aldehyde Impurity 22065‐85‐6
D Donepezil 3‐Hydroxy Impurity 2097683‐67‐3
D Donepezil Open‐Ring Keto Acid 197010‐25‐6
D Product: DOPAMINE IMPURITIES
D 3‐O‐Methyldopamine
554‐52‐9
1477‐68‐5
D 4‐O‐Methyldopamine 645‐33‐0
D Product: DORZOLAMIDE IMPURITIES
D Dorzolamide EP Impurity B/ Dorzolamide Related Compound B 120279‐37‐0
D Dorzolamide EP Impurity D/ Dorzolamide Related Compound D (N‐Desethyl Dorzolamide)
154154‐90‐2
164455‐27‐0
D Product: DOXAZOSIN IMPURITIES
D Doxazosin EP Impurity A/ Doxazosin Related Compund D 3663‐80‐7
D Doxazosin EP Impurity B/ Doxazosin Related Compund A 70918‐74‐0
D Doxazosin EP Impurity C/ Doxazosin Related Compund F 617677‐53‐9
D Doxazosin EP Impurity D/ Doxazosin Related Compound B 28888‐44‐0
D Doxazosin EP Impurity E/ Doxazosin Related Compund E 27631‐29‐4
D
Doxazosin EP Impurity F/ Doxazosin Related Compund C (Terazosin EP Impurity A/ Prazosin EP Impurity A/ Alfuzosin EP
Impurity B) 23680‐84‐4
D Doxazosin EP Impurity G ( Prazosin EP Impurity C/ Terazosin EP Impurity C/ Terazosin Related Compound A)
60547‐97‐9
60548‐08‐5
D Doxazosin EP Impurity H (Prazosin EP Impurity E/ Terazosin EP Impurity E/ Terazosin Related Compound C)
102839‐00‐9
1486464‐41‐8
104965‐50‐6
D Product: DOXEPIN IMPURITIES